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Abstract 
It is well documented that the administration of succinylcholine (SCh), also 
known as suxamethonium, with general anesthesia causes muscle 
fasciculations, which may cause severe postoperative myalgia. However, such 
an association has not been well documented. Many authors have postulated 
that such pain is secondary to damage produced in the muscle during 
fasciculation. As a result, it is acceptable standard anesthetic practice to aim to 
prevent fasciculations when administering SCh during the administration of 
general anesthesia. 
Today, studies utilizing subtherapuetic doses of nondepolarizing 
neuromuscular blockade have shown the greatest promise in reducing 
postoperative myalgia secondary to the use of SCh. This study has examined 
and compared the efficacy of pretreatment with lidocaine, atracurium, and the 
combination of the two in relation to the incidence and severity of postoperative 
myalgia. As statistical significance was not expected with such a small pilot 
population, this study was designed to determine the feasibility of conducting a 
larger study. Additionally, trends within this population were further examined to 
determine clinical significance. 
. This study was a prospective, double-blinded randomized clinical study 
utilizing 15 subjects who met inclusion criteria, and gave informed consent to 
participate in the study. Each patient was randomly assigned to one of three 
experimental groups that included lidocaine, atracurium, or a combination of the 
two medications. Each group followed the same study protocol. 
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Participants were followed every 24 hours for three days. Data collected was 
based on a postoperative myalgia survey of 14 questions to ascertain myalgia 
from routine postoperative discomfort. The answers were then graded on a 
Likert scale (postoperative myalgia evaluation scale). In this way data collection 
not only included those having myalgia, but also took into account the intensity of 
postoperative myalgia. Data analysis compared the groups, looking for a 
statistical significant difference to determine whether one pretreatment 
medication was better than another in preventing postoperative myalgia. 
As expected, statistical significance was not found among the three 
pretreatment groups in relation to amount or intensity of postoperative_ myalgia. 
In other words, one pretreatment group did not show improved efficacy over 
another pretreatment group. However, several trends were identified, suggesting 
that each pretreatment medication may have advantages and disadvantages that 
may signify clinical significance, although not statistically significant. 
In conclusion, this study proved to be feasible, and identified many new 
factors such as physical health status, cigarette smoking, medication therapy 
prior to surgical intervention, surgical type, and surgical position that may 
contribute to the phenomena of postoperative myalgia. Therefore, further 
research in this area is warranted. 
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Chapter I 
Introduction 
Griffith & Johnson documented the first case of using human neuromuscular 
blockade during general anesthesia in 1942. Unauthenticated Curare, by 
Squibb, was administered to 25 patients experimentally. The investigators found 
that it provided excellent muscle relaxation without detrimental effects to the 
patient. However, their study concluded the following:_ 
Its scope of usefulness is limited because of its somewhat fleeting action, and 
because it is in no sense an anesthetic agent. It is a potentially dangerous 
poison, and should be used only by experienced anesthetists in well-equipped 
operating rooms; but we have been so much impressed by the dramatic effect 
produced in every one of our patients that we believe this investigation should 
be continued (p. 420). .- ·: ,J '= 
Today, intraoperative administration of neuromuscular blocking agents is 
routinely utilized to facilitate endotracheal intubation associated with general 
anesthesia, as well as provide skeletal muscle relaxation for optimal surgical 
conditions (Stoelting & Miller, 2000). Multiple new pharmacological agents, 
which provide akinesia, have been developed and refined over the last fifty 
years. In each instance, the goals of scientists have been to develop agents that 
provide the maximum desirable muscular paralysis while minimizing the 
undesirable side effects of the agents. Additional uses of neuromuscular 
blocking agents during this same time period have expanded to patient care 
areas outside the operating room, enabling other providers to administer such 
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agents. Situations where neuromuscular blocking agents may be used in the 
care of patients outside of the surgical arena include assisting ventilation in 
critically ill patients within the Intensive Care Unit, decreasing the muscle activity 
during electroconvulsive therapy, and providing an emergent airway to a patient 
within the Emergency Department (Pino & Basta, 1998). Such agents have 
become a mainstay not only for the anesthesia providers' arsenal, but for other 
medical professionals as well. 
The Neuromuscular Junction 
As described in Table 1, there are currently eleven distinct neuromuscular 
blocking agents available within the United States. Skeletal muscle paralysis is 
produced by the action of these agents and their ability to "block" or interrupt 
nerve impulses at the neuromuscular junction. Based on the mechanism of 
nerve interruption, onset, and duration (se� Table 1), each agent is classified as 
either a depolarizing or a nondepolarizing agent (Stoelting, 1987). Pertinent to 
understanding this author's work is the definition and description of how 
neuromuscular blocking medications act at the cellular level. Therefore, for 
clarity and unification, a brief review from this authors perspective will be 
presented in the following section. A description of the normal neuromuscular 
junction and the associated mechanisms of action for each class of 
neuromuscular blocking agents will be reviewed. 
The neuromuscular junction, also referred to as a myoneural junction, is the 
area between a prejunctional motor nerve fiber and a postjunctional skeletal 
muscle (Resnick & Henze, 2000). Transmission of a nerve impulse depends 
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Table 1: Neuromuscular Blocking Agents 
Agent Classification Onset Duration Action 
Succinylcholine Depolarizing 30-60 sec 5-15 min Ultrashort 
(SCh) 
Mivacurium Nondepolarizing 2-3 min 20-30 min Short 
Atracurium Nondepolarizing 2-3 min 30-60 min Intermediate 
cis-Atracurium Nondepolarizing 2-3 min 30-60 min Intermediate 
Rocuronium Nondepolarizing 1-1.5 min 30-60 min Intermediate 
Vecuronium Nondepolarizing 3-4 min 30-60 min Intermediate 
Doxacurium Nondepolarizing 12 min 60-90 min Long 
· Metacurium Nondepolarizing 1-2 min 60-90 min Long 
Pancuronium Nondepolarizing 2-3 min 60-90 min Long 
Pipecuronium Nondepolarizing 3-4 min 60-90 min Long 
d-tubocurare Nondepolarizing 3-4 min 60-90 min Long, but no 
(OTC) longer 
available 
Adapted from Morgan & Mikhail, 1996 
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largely on the influx of calcium at this junction. Such an influx of calcium ions 
causes a release of the neurotransmitter acetylcholine from the nerve terminal. 
Once acetylcholine binds to the postjunctional receptors on the skeletal muscle, 
changes in membrane potential create an action potential difference that leads to 
skeletal muscle contraction (Stoelting & Miller, 2000). Relaxation of the skeletal 
muscle is facilitated by the enzyme acetylcholinesterase. This enzyme 
hydrolyzes acetylcholine, thus, eliminating from the neuromuscular junction the 
principle neurotransmitter responsible for the propagation of action potentials in 
skeletal muscle, which subsequently leads to muscular relaxation (Stoelting & 
Miller, 2000). 
Depolarizing Neuromuscular Blockade 
Of the eleven neuromuscular blocking agents available within the United 
States, only succinylcholine (SCh) is classified as a depolarizing agent. 
Chemically, its structure can be described as two acetylcholine molecules bound 
together. Therefore, SCh mimics the action of acetylcholine at the 
neuromuscular junction by creating an action potential within the skeletal muscle 
after the opening of prejunctional sodium channels, and causing a myoneural 
depolarization (Stoelting & Miller, 2000). However, because hydrolysis of SCh 
within the synaptic cleft is much slower than acetylcholine, each muscle cell 
remains depolarized, and the numerous action potentials which occur result in 
muscle twitches or fasciculations that can be observed. Relaxation of the 
skeletal muscle occurs because SCh occupies the postjunctional receptor site, 
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and sodium channels cannot reopen until the end plate repolarizes (Morgan & 
Mikhail, 1996). 
Because of its chemical structure and metabolism by plasma cholinesterase, 
SCh has the two most desirable effects of any skeletal muscle relaxant available 
today: (1) fast onset and (2) short duration. Such properties allow for quicker 
control of the airway following loss of consciousness after the induction of a 
general anesthetic, facilitation of endotracheal intubation, and faster recovery of 
spontaneous respiration following muscular paralysis. Therefore, the use of SCh 
allows for safer care to the unconscious anesthetized patient when rapid 
securing of the airway is necessary. 
Nondepolarizing Neuromuscular Blockade 
Currently, there are ten nondepolarizing neuromuscular blocking agents 
available for use in the United States. All of the their mechanisms of action are 
similar and involve the competitive inhibition ·of acetylcholine at the postjunctional 
receptor on the skeletal muscle at the level of the neuromuscular junction. 
Excessive quantity of non_depolarizer molecules at this site effectively prevents 
ion permeability, cellular depolarization, and ultimately inhibits the generation and 
propagation of action potentials. This disruption of cellular electrical activity 
allows for flaccidness of the skeletal muscle to predominate (Morgan & Mikhail, 
1996). 
Nondepolarizing neuromuscular blocking agents are classified into three 
groups according to their duration of action. These groups include short acting 
agents, intermediate acting agents, and long acting agents. However, in spite of 
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the suggestion made by the name, even the individual drugs in the short acting 
group have a longer time until onset and longer duration than SCh (see Table 1 ). 
SCh remains the best medication currently available for enabling an anesthesia 
provider to rapidly secure the surgical patient's airway. The ability to safely, 
efficiently, and rapidly control the respiratory functions and airway is one of the 
most important actions of an anesthesia provider (Morgan & Mikhail, 1996). 
Despite many desirable effects, SCh also displays many adverse actions, 
which range from nuisance to serious. These side effects are listed in Figure 1. 
Obviously, the severe reactions are more important (Stoelting� 1987). Many 
studies exist on these reactions and conditions and much is known about these 
complications and their treatments. There is, however, a paucity of information · 
regarding surgical patients and post-SCh administration myalgia. This paper will 
concentrate on the iatrogenic causes and treatments for SCh-induced 
postoperative myalgia, as it relates to the "gate control theory of pain". 
Succinylcholine-induced Postoperative Myalgia 
Past studies have indicated that the incidence of SCh-induced postoperative 
myalgia ranges from 1.5% - 89%, with the most common incidence being 50% 
(Wong & Chung, 2000). Certainly this is a sizable variation, and the lack of 
consistent scientific data on this subject is another important factor that 
encourages this author's current study. The most postulated mechanism for 
myalgia following SCh administration is believed to be from what is termed 
fasciculation (Wong & Chung, 2000). This phenomenon occurs almost 
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Adverse Side Effects of Succinylcholine 
Cardiac dysrhythmias 
Sinus bradycardia 
Junctional rhythm 
Sinus arrest 
Fasciculations 
Hyperkalemia 
Myalgia 
Myoglobinemia 
Increased lntraocular pressure 
Increased lntragastric pressure 
Trismus 
Allergic reactions 
Trigger for Malignant Hyperthermia 
Adapted from Stoelting & Miller, 2000 
Figure 1: Adverse Side Effects of Succinylcholine 
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immediately after the administration of SCh, and is observed as uncoordinated , 
uncontrol lable, vigorous twitching of single muscle groups innervated by single 
motor nerve fibers (Anderson, Anderson, & Glanze, 1 998 pp. 61 6). It occurs 
over the entire body without synchronous activity, allowing for shearing forces 
and biochemical damage to occur to the muscle cel ls and tissues. Such damage 
is believed to be a major contributing factor leading to postoperative muscle 
soreness (myalgia) (Wong & Chung, 2000). 
Although it was originally postulated that postoperative muscle pain was 
linked to the use of SCh and its depolarizing action that caused fasciculations, 
the exact pathogenesis is still unknown. Many studies have concluded that the 
mechanism for SCh-induced fasciculation is a prejunctional phenomenon. 
Similarly, respected researchers have confirmed the correlation between 
fasciculation and SCh administration (Kitamura S, Yoshiya I, Tashiro C, & Nefishi 
T, 198 1 ). However, it does not appear that the same relationship occurs 
. . 
between SCh-induced fasciculation and postoperative myalgia (Sosis, Broad, 
Larijani & Marr, 1 987). Studies attempting to correlate muscle damage 
secondary to fasciculation, with changes in serum creatine phosphokinase levels, 
lactic acid levels, and electrolyte changes, have all discredited this theory. No 
studies to date have confirmed a statistically significant relationship between 
muscle damage secondary to the use of SCh, and postoperative myalgia (Wong 
& Chung, 2000). Therefore, these findings suggest that such muscle pain must 
occur from some additional mechanism, other than exclusively from muscular 
fasciculation. 
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The results of some studies have yielded data that suggests postoperative 
myalgia may not be associated at all with fasciculation, nor is it associated with 
the use of SCh (Mingus, Herlich, & Eisenkraft, 1990). Recent studies have 
demonstrated that no significant difference in postoperative myalgia is found 
between those subjects who receive SCh and groups of subjects that receive a 
nondepolarizing agent (Mingus, Herlich, & Eisenkraft, 1990). Few studies have 
determined that myalgia may occur even in the circumstance when SCh 
administration is avoided ·and only nondepolarizing agents are utilized (Trepanier, 
Brousseau, & Lacerte, 1988). Regardless of the cause, for those individuals 
who experience pain, the occurrence of postoperative myalgia is viewed as 
unacceptable. A closer look at the complex process of how pain is sensed, 
transmitted, modulated, and perceived may contribute to a better understanding 
of how to treat patients who experience this type of discomfort. 
Myalgia 
Postoperative myalgia is usually self-limiting in duration, ·and occurs up to 
three days postoperatively, with 24 to 48 hours being the most prominent time 
frame (Mikat-Stevens, Sukhani, Pappas, Fluder, Kleinman, & Stevens, 2000). It 
is often compared to the feeling one obtains after aggressively working the 
muscles, as may result from a period of strenuous physical exercise. It may 
occur in the chest wall, the upper abdomen, shoulders, neck, and back 
(Stoelting, 1987). Although the extent of muscle pain is generally mild, some 
patients may experience debilitating effects requiring bed rest and analgesic 
therapy for several days postoperatively. Even though the origin of such pain 
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remains unknown, explanations for the wide variance in occurrence and severity 
can be explained by the gate control theory. 
· This theory was first proposed in 1965, and continues to be the basis for 
effective postoperative pain management (Melzack & Wall, 1965). Melzack and 
Wall suggested that pain is transmitted from a peripheral site, such as the skin 
(or a muscle), to a specialized group of cells within the dorsal horn of the spinal 
cord known as the substantia gelatinosa. This area acts as a gate and responds 
in one of two ways: opening to transmit signals (as in the noxious stimuli 
associated with myalgia) to higher centers, or closing and thereby inhibiting the 
transmission (as by the actions of analgesics). 
Although such a theory may sound simple, there are a complex series of 
physiologic responses that occur between the area of tissue damage 
(fasciculation) and the perception of pain (postoperative myalgia). Such 
complexity is referred to as nociception. Four physiologic processes trigger 
nociception, or pain perception: transduction, transmission, modulation, and 
perception (Ferrante, 1998). 
Transduction, the first response to occur, happens upon administration of 
SCh. For those who believe fasciculation has a correlation to postoperative 
myalgia, it is theorized that the muscle tissue becomes injured by the 
fasciculation, and potassium is released into the extracelluar fluid as a result of 
this injury or damage. Potassium is one of many pain-producing substances that 
stimulate a specialized group of sensory receptors called nociceptors. Other 
substances include hydrogen, seratonin, histamine, prostaglandins, and 
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bradykinins. Collectively these are known as algesic agents and, upon 
stimulation of the nociceptors, they cause electrochemical events at sensory 
nerve endings (Sackett & Cannon, 2000) . 
At this point the second step of nociception, transmission, occurs. The gate is 
opened as the propagation of electrical events is sent to the higher centers of the 
peripheral nervous system (PNS) and central nervous system (CNS). Such 
stimulation allows for the fourth process: perception of pain (Ferrante, 1998). 
Substance P is released within the cerebral tissue upon stimulation. It is this 
substance that conveys pain information in the cognitive centers of the brain and 
thereby allows for this stimulation to be identified as pain perception and 
associated responses enacted. Although transmission to the CNS occurs 
primari ly through small diameter A-delta and C-fibers, interconnections between 
other sensory pathways can occur. One such pathway includes A-beta and A­
alpha fibers. Stimulation of these large-diameter, fast, myelinated fibers causes 
the gate to close and prevents or inhibits transmission to the higher neural 
centers (Sackett & Cannon, 2000) . Modulation, the third process, prevents the 
release of Substance P and consequently the perception of pain (Sackett & 
Cannon, 2000). It is this author's bel ief that it is this interplay between fibers .that 
may most plausibly provide the explanation for the occurrence of such a wide 
range ( 1.5% - 89%) and severity of reported postoperative myalgia. 
Although studies up to this point in time have not determined the mechanism 
by which postoperative myalgia occurs, it has been determined that the fol lowing 
groups of individuals have a higher incidence of exhibiting such postoperative 
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muscle soreness: females greater than males, individuals between the ages of 8 
and 50 (Mingus, Shamsi, Recant, Eisenkraft, 1 996) , those persons who are 
ambulatory immediately after surgery (Oxorn, Whatley, Knox, & Hooper, 1 992) . 
those patients undergoing minor procedures, and people who are less physically 
fit than would be optimal (Newman & Loudon, 1 966). Additionally, without any 
firm explanation, it has been observed that pregnancy appears to decrease 
postoperative myalgia (Crawford, 1 -971 ) .  Lastly, there does not appear to be an 
association with different ethnic backgrounds (Houghton, Aun, Gin, Lau, & Oh, 
1 993) . 
Many techniques have been attempted to prevent postoperative myalgia, and 
it seems as though the science has come full circle in the last 50 years. The 
current "gold standard" for prevention of postoperative myalgia in patients who 
receive SCh is through use of pretreatment doses of nondepolarizing agents. 
Despite critical opinions that such agents may cause difficulty with intubation, 
weakness, diplopia, difficulty in breathing, and prolongation of neuromuscular 
blockade, such agents consistently cause a 30% reduction of postoperative 
myalgia (Pace, 1 990). Until further studies can demonstrate an alternative that 
constantly and dependably reproduce the same or similar outcomes with regard 
to the reduction of postoperative myalgia in patients who receive SCh, 
nondepolarizing agents will continue to be the current standard of treatment. 
Many studies have implicated the use of lidocaine for reliable prevention of 
postoperative myalgia in association with SCh use. Of the current available 
studies, all but one have suggested that lidocaine is of equal efficacy, and is 
1 2  
safer than the traditional treatment of nondepolarizing agents. Additionally, 
multiple authors' studies agree that combination therapy with lidocaine and a 
nondepolarizing neuromuscular blocking agent has shown to more significantly 
improve outcomes of measured pain in subjects receiving SCh perioperatively. 
Therefore, the focus of this study will be to compare the differential effects of 
atracurium and/or lidocaine on SCh-induced postoperative myalgia as it relates 
to the gate control theory of pain. The null hypothesis is as follows: 
Null Hypothesis 
There will be no difference in postoperative myalgia in subjects receiving SCh 
who also receive one of three pretreatments: atracurium, lidocaine, or the 
combination of atracurium and lidocaine. 
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Chapter II 
Review of the Literature 
The Development of Succinylcholine 
· 1n 1906, Hunt & Taveau were the first to synthesize SCh. They were looking 
for agents that would maintain hemodynamics during general anesthesia in 
anesthetized animals (Hunt & Taveau, 1906). Since they were using SCh in 
conjunction with d-tubocurarine (DTC), the muscle relaxant properties of SCh 
were not recognized. In fact, this association was not made until 1949 (Churchill­
Davidson, 1984). Within a year of this discovery, SCh was being utilized in small 
doses as a muscle relaxant during general anesthesia in humans (Foldes, 
McNall, & Borrego-Hinojosa, 1952). Today, this drug continues to be widely 
utilized by anesthesia professionals in the implementation of muscular paralysis 
for subjects undergoing surgical intervention. 
Side Effects of Succinylcholine 
By the end of 1952 adverse side effects of SCh were first being noted. 
Although not the focus of the original study on SCh, the initial side effect 
identified was that of prolonged respiratory depression. This was attributed to 
the administration of "unnecessarily high doses of succinylcholine" (Foldes, 
McNall, & Borrego-Hinojosa, 1952, p. 600). However, further study resulted in an 
association of SCh termination with plasma cholinesterase, the mechanism by 
which SCh is metabolized, and the cause for occasional extended action of SCh 
was identified. As a result of their research, prolonged respiratory depression in 
subjects who were administered SCh was correlated to those subjects who had 
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low levels of plasma cholinesterase (Foldes, McNall, & Borrego-Hinojosa, 1952). 
Others confirmed such findings the very same year (Evans, Gray, Lehmann, & 
Silk, 1952). 
Reports of a possible relationship between fasciculation and postoperative 
myalgia started infiltrating the literature in 1952 (Brodsky & Ehrenwerth, 1980). 
In one study comparing inpatient subjects to outpatient subjects, Churchill­
Davidson found that SCh caused marked postoperative myalgia despite the fact 
that the surgical procedure may have been minor (Churchill-Davidson, 1 954). 
Interestingly enough, the author compared groups that were equal in terms of 
group size and age, and found that outpatient subjects had a significantly higher 
rate (66%) of muscle pain than was observed in the inpatient subjects population 
(13.9%). This is a similar finding when compared to the majority of today's 
studies (Wong & Chung, 2000). 
Treatments for the Prevention of Postoperative Myalgia 
The previously noted study by Churchill-Davidson was the first to attempt to 
find a treatment for the prevention of postoperative myalgia. The first use of 
gallamine, a nondepolarizing neuromuscular blocking agent, was used in 
conjunction with SCh in an effort to abolish fasciculation and prevent 
postoperative myalgia. Churchill-Davidson found that pretreatment with small 
doses of gallamine, prior to the administration of SCh, totally abolished 
fasciculation within both groups. Additionally, although not completely resolved, 
the incidence of postoperative myalgia for outpatient subjects decreased from 
66% to 40%. Complete abolishment of both fasciculation and postoperative 
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myalgia for the inpatient subject group was achieved. These initial findings 
appeared to offer support that fasciculation and postoperative myalgia were 
directly related (Churchill-Davidson, 1954). 
Further studies by Foster, in 1960, determined the incidence of myalgia to be 
increased among ambulatory outpatient subjects. Additionally, he identified 
many facts about myalgia in relation to SCh administration, which still hold true 
today. These included the following: Postoperative myalgia occurs less 
frequently in subjects over the age of 60, there is a low incidence of pain in 
children, and muscle pains varied in accordance to the type of surgery (Foster, 
1960). Furthermore, he confirmed that gallamine lowered the incidence and 
severity of postoperative myalgia. Despite this encouraging finding, he 
concluded that the use of nondepolarizing agents, as a pretreatment prior to 
SCh, should not be recommended. Such agents were found to cause marked 
respiratory depression or airway difficulties at the termination of the procedure 
(Foster, 1960). Others, throughout the literature of that time, agreed with 
Foster's supposition. In 1977, Baraka declared the competitive and antagonistic 
affects of SCh were thought to delay the onset and decrease the degree of 
neuromuscular blockade. Therefore, for purposes of preventing SCh-induced 
postoperative myalgia, choosing a nondepolarizing agent for intubation and 
completely avoiding the administration of SCh would be a better choice within the 
context of the anesthetic plan (Baraka, 1977). 
Because of such effects associated with the use of nondepolarizing agents as 
a pretreatment for the prevention of postoperative myalgia in subjects who have 
17 
received SCh ,  other methods have been investigated in the last 50 years that 
have followed Churchi l l-Davidson's seminal work in th is area. With in the 
literature, there are at least 1 3  other treatments that have been stud ied in an 
attempt to prevent or lessen postoperative myalg ia. These include self-taming , 
stretching exercises , magnesium sulfate , propofol , vitamin C,  dantrolene, 
lidocaine, calcium gluconate, benzodiazepines, chlorpromazine, 
aspirin/nonsteroidal anti-inflammatory drugs, phenytoin, altering induction agents , 
and dosage/timing of SCh administration (Wong & Chung,  2000) . Some have 
shown to be successful ,  whi le others have fai led . The following section wil l  
further describe the rational for, and success or fai lure of, each of these 
treatments as they appear in the current literature. 
Self-taming 
I n  much the same way a small dose of a nondepolarizing agent is given as a 
pretreatment for the prevention of myalg ia associated with SCh administration , 
giving small doses of SCh prior to the fu ll dose has been attempted for the same 
reason .  This idea is known as "self-taming" (Baraka, 1 977). It is thought that 
the taming effect desensitizes the neuromuscular junction . Therefore , excitation 
between the nerve terminals and the muscular membrane cannot occur al lowing 
for decreased fasciculation . Additionally, unl ike the affects ·caused by 
pretreatment with a nondepolarizing agent, onset and duration of the block can 
be preserved (Baraka, 1 977). 
In  1 979, Brodsky and Brock-Utne found a 25% incidence of fasciculation 
when using a self-taming technique as described by Baraka . This is very simi lar 
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to Baraka's results of a 20% incidence. However, unlike Baraka, Brodsky and 
Brock-Utne found no relationship between this decrease in fasciculation and 
postoperative myalgia. Therefore, they concluded there was no advantage to 
utilizing a "self-taming" technique for the purpose of preventing postoperative 
muscular soreness in conjunction with SCh administration. 
Like Churchil l-Davidson and Foster's studies, Brodsky and Brock-Utne (1979) 
found an increased incidence of postoperative myalgia in subjects who ambulate 
(outpatient subjects). However, they emphasized the fol lowing:- "muscle aches 
may occur postoperatively even when succinylcholine has not been used, and it 
is impossible to differentiate SCh-induced myalgia from muscle soreness due to 
other causes" (p. 267). This provides further supportive evidence for what we 
believe today, which is that fasciculation and postoperative myalgia may not be 
directly associated. Therefore, prohibiting fasciculation may not be the 
mechanism by which to improve patient outcomes in relationship to postoperative 
muscular pain. 
Although true, the above statement by Brodsky and Brock-Utne takes into 
account only part of the phenomenon. There are numerous studies throughout 
the literature comparing the incidence of postoperative myalgia with the use of 
depolarizing agents and nondepolarizing agents, and these studies fail to support 
Brodsky and Brock-Utne's statement. Trepanier, Brousseau, and Lacerte (1988) 
compared SCh with atracurium in relation to postoperative muscle pain. The 
incidence of postoperative myalgia among the group that received SCh was 
76%, and the group who received atracurium was 23%. Therefore, these 
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authors concluded the use of atracurium significantly reduced postoperative 
myalgia in comparison to SCh. 
However, when pretreatment doses of a nondepolarizing agent are utilized 
prior to the administration of SCh, and these subjects are compared to the 
members of a group who receives only a nondepolarizing agent, there is 
evidence to support Brodsky and Brock-Utne's statement. Deehan, Henderson, 
and Stewart (2000) compared subjects who received SCh after being pretreated 
with gallamine to subjects who received only mivacurium. Although their findings 
found a 26% incidence of postoperative myalgia in the pretreated SCh group, 
and only a 9.5% finding in the mivacurium group, they were not statistically 
significantly different. These findings provide additional evidence that 
postoperative myalgia may result from causes other than SCh exclusively. 
The study findings of Mikat-Stevens, Sukhani, Pappas, Fluder, Klienman and 
Stevens (2000) corresponded to the findings of the research study conducted by 
Deehan and associates. These investigators compared a group of subjects who 
received SCh following pretreatment with OTC to a group of subjects who only 
received mivacurium. Again, they found that the pretreated SCh group had an 
increased incidence of myalgia at 2 1  %. These findings, however, were not 
significantly different from the 1 8% incidence noted in the mivacurium group. 
Thus, like Deehan and associates, these authors concluded that pretreating 
subjects with nondepolarizing neuromuscular blocking agents, prior the 
administration of SCh, does not cause a decrease in postoperative myalgia. 
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Stretching Exercises 
It is known that athletes who stretch prior to exercise have decreased muscle 
damage and pain afterwards (Harris, 1984). MaGee & Robinson (1987) 
theorized that perhaps the same would be true for subjects undergoing 
anesthesia requiring the use of SCh for endotracheal intubation. They postulated 
that the stretch receptors on the muscle fibers could undergo desensitization in 
much the same way self-taming occurs. Their study concluded with a significant 
finding of only 15% of the experimental stretching group having postoperative 
myalgia, while 55% of the control group reported pain. Thus, signifying that 
stretching prior to the administration of SCh decreased postoperative myalgia. 
Although not the focus of this study, it is interesting to note that Ma Gee & 
Robinson ( 1987) also found a correlation between fasciculation and the degree 
of pain: The greater the measured fasciculation, the greater degree of reported 
postoperative pain. Interestingly, in many of today's studies, this correlation does 
not appear to occur. 
Magnesium Sulfate 
A classic example where absence of fasciculation does not coincide with an 
absence of postoperative pain involves the administration of magnesium. 
Specifically, pretreatment of magnesium sulfate does not diminish complaint of 
postoperative discomfort following the administration of SCh. Theoretically, 
magnesium sulfate has neuromuscular blocking properties and should abolish 
fasciculation. If the absence of fasciculation equates to the absence of 
discomfort, subjects adequately treated with magnesium sulfate should not 
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fasciculate, and so should have their pain prevented. A study performed by 
Chestnutt and Dundee (1985) found that magnesium significantly decreased 
fasciculation, nearly abolishing it. However, only slight decreases were identified 
in relation to postoperative myalgia in their study subjects. 64% of the treated 
group had postoperative pain, as opposed to 80% of the untreated group, not a 
significant difference in regards to their study. 
Stacey, Barclay, Asai, & Vaughan (1995) confirmed Chestnutt and Dundee's 
finding. They discovered a significant decrease in fasciculation with the use of 
magnesium sulfate, but no difference in postoperative myalgia. Oddly, in similar 
fashion to the findings of Chestnutt and Dundee, serum potassium levels were 
found to be normal. Therefore, despite the abolishment of fasciculation and 
normal potassium levels, subjects pretreated with magnesium sulfate continue to 
have postoperative muscle soreness. Therefore, it was concluded that 
magnesium sulfate shows no promise in being a pretreatment for the prevention 
of postoperative myalgia in subjects who receive SCh. 
Propofol 
In terms of fasciculation, two recent studies have shown agreement with the 
above noted findings. First, Mingus, Shamsi, Recant, and Eisenkraft's (1996) 
study consisted of the following three groups: those who received thiamylal/SCh 
in group one, propofol/ SCh in group two, and propofol/saline in group three. All 
groups were demographically comparable, and none demonstrated significance 
in incidence or severity of postoperative myalgia despite significant differences in 
measured fasciculation between groups' one, two, and three. Although group 
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three did not receive SCh, 30% of the subjects in this group reported 
postoperative pain. In contrast, 50% of the subjects within group two, who 
received SCh, complained of postoperative myalgia. These results were not 
considered significant, therefore, allowing Mingus and associates to conclude 
that postoperative myalgia was not associated with fasciculation. 
Manataki, Arnaoutoglou, Tefa, Glatzounis, and Papadopoulos (1999), 
performed a study comparing two groups of subjects. Both groups received 
propofol and SCh for induction, but differed in their maintenance of anesthesia. 
Group one was maintained with isoflurane, while group two received continuous 
propofol. No significant correlation was found between fasciculation, 
postoperative myalgia, or elevations in CPK between the group who had been 
maintained using propofol, as compared to the group who was maintained with 
isoflurane. Therefore, the authors concluded that fasciculation does not have a 
correlation with muscle damage. Additionally, they contended that postoperative 
myalgia and muscle damage are not caused by the same mechanism. 
Vitamin C 
Vitamin C is known to decrease muscle pain and soreness after 
unaccustomed exercise. It provides protection to the endothelial lining of 
capillaries, therefore preventing damage to muscle fibers (Syed, 1966). Gupte 
and Savant (1971 ) showed a decreased significance in the incidence of 
postoperative myalgia with the administration of vitamin C perioperatively. 
Currently, however, there are no studies that compare this intervention with other 
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treatments (Wong & Chung, 2000). Therefore, this remains an area for future 
study that may provide an alternative treatment for postoperative myalgia. 
Dantrolene 
Collier (1978) theorized that the more calcium released from the sarcoplasmic 
reticulum within the muscle during depolarization, the greater the speed and 
strength of resulting fasciculations. Ultimately, stronger fasciculations lead to 
greater muscle damage and results in increased postoperative myalgia. 
Confirmation of this became reality in Collier's first study. In this investigation, he 
found an inverse relationship between calcium and potassium in those subjects 
who developed pain and concluded that postoperative myalgia was a result of 
muscle fiber damage, secondary ·to fasciculation, that was caused by the 
enhanced release of calcium. 
Since dantrolene interferes with intercellular calcium transfer, Collier ( 1 979) 
felt it was an appropriate medication to decrease fasciculation and postoperative 
myalgia. In his second study, 98 subjects were given dantrolene orally two hours 
prior to surgery. Not only did he find a significant difference in the strength of 
muscle fasciculation and potassium levels, he also found that myalgia decreased 
from 56% to 4% between the pretreated group and those who were not 
pretreated. Additionally, unlike the use of nondepolarizing agents as a 
pretreatment, he did not identify any alteration in the action of SCh in conjunction 
with dantrolene administration. Therefore, he concluded dantrolene to be an 
efficient treatment for the prevention of postoperative myalgia in subjects who 
received SCh. 
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Another study with dantrolene performed by Gysai, Delisle, and Bevan (1 982) 
failed to show a reduction in postoperative myalgia. However, this study utilized 
small doses of intravenous dantrolene instead of the oral form. This was not the 
first instance identified in the literature where an intravenous form of a medication 
under investigation failed to have the same outcome, in reference to 
postoperative myalgia, as the oral form. The authors recommended further study 
of this subject matter in order to assess whether there was an association 
between route of administration and postoperative discomfort following 
intravenous SCh administration. 
Fol lowing Collier's lead, and postulating that postoperative myalgia is a result 
of muscle damage, Laurence ( 1 985) performed a study attempting to show a 
correlation between dantrolene pretreatment and muscle damage. Rises in 
myoglobin were measured to predict the amount of muscle damage. He 
hypothesized that pretreated subjects would show decreased myoglobin levels, 
thereby, indicating significantly less muscle damage had occurred. As 
postulated, significant differences in the amount of myoglobin were found among 
pretreated subjects verses those subjects who were not pretreated. Following 
analysis of the data col lected in his study, this author concluded that his results 
agreed with Collier. His final conclusion was that oral dantrolene could 
potential ly be beneficial in the prevention of postoperative myalgia . 
. Lidocaine 
JE Usubiaga, Wikinski, JA Usubiaga, and Molina (1967) were the first to show 
that pretreatment with intravenous lidocaine prevented postoperative myalgia, as 
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well as a decrease in muscle soreness. They found minimal side effects 
associated with lidocaine when it was given at doses of 1.5 mg/kg. In 1973, 
Haldia, Chatterji, and Kackar replicated such findings by using 3-4 mg/kg of 
lidocaine, showing decreased postoperative myalgia. Today, 1.5 mg/kg is the 
most often used dose, as these past studies have shown equal efficacy between 
this dose and higher doses. Additionally, such a dose is well below the toxicity 
level of lidocaine. 
In much the same way Collier found an inverse relationship among potassium 
and calcium in relation to the use of dantrolene, Chatterji, Thind, and Daga 
(1983) found a similar relationship with the use of lidocaine. Unlike their 
predecessors, who believed that lidocaine prevented soreness by producing a 
sedative effect, these authors concluded that lidocaine stabilized the cell 
membrane and consequently restricted ionic movement. The effect of lidocaine 
in subjects who received SCh was the suppression of muscle damage and the 
prevention of postoperative myalgia. 
Calcium Gluconate 
Shrivastava, Chatterji, Suman, and Daga (1983) further investigated the 
relationship between SCh administration and cellular damage. Specifically, they 
examined the previously observed inverse relationship of increased serum 
potassium and decreased serum calcium in relation to SCh-induced 
postoperative myalgia. These individuals theorized that the administration of 
calcium gluconate prior to the administration of SCh would prevent postoperative 
myalgia. Although they could not identify the mechanism by which this occurred, 
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they nonetheless observed that calcium gluconate significantly reduced the 
incidence of muscle pains from 45% to 5%. Additionally, the severity of pain was 
likewise reduced. A principle conclusion of these authors was that since similar 
studies were limited, further research on calcium gluconate and its association 
with postoperative myalgia was indicated before the use of this intervention could 
be established as a beneficial treatment. 
Benzodiazepines 
As well as myoglobin changes, studies have found that the administration of 
SCh can also cause electrolyte and other biochemical changes at the cellular 
level. As the above studies have eluded, these alterations are hypothesized to 
be a result of depolarization and muscle damage from fasciculation. In 
agreement with the gate control theory, some studies have attributed increases 
in serum potassium and creatine phosphokinase (CPK) as causative factors for 
postoperative myalgia (Fahmy, Malek, & Lappas, 1979). Fahmy and associates 
found that pretreatment with diazepam prior to SCh administration prevented 
fasciculations, hyperkalemia, and subs�quent rises in CPK. Thus, they 
concluded this intervention led to a significant decrease in postoperative myalgia. 
In their work, only 12.5% of subjects receiving benzodiazepines experienced 
postoperative myalgia as compared to 65% of subjects in the untreated group. 
Eisenberg, Balsley, and Katz (1979) had similar results of decreased muscle 
pain in subjects who received SCh as a component of their anesthetic plan, but 
who were pretreated with diazepam. In their study, only 13% of the treatment 
group displayed postoperative discomfort. This is contrasted to 33% of the 
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control group's subjects. Although, serum potassium levels remained normal in 
their study subjects, unlike Fahmy and associates, they found that CPK was 
elevated within the pretreatment group. Reasoning for this finding remains a 
mystery, and unlike the previous study, decreases in postoperative myalgia 
occurred despite a rise in CPK. 
Prior to these two studies, Verma, Chatterji, and Mathur (1978) had also 
concluded that pretreating with diazepam decreased the incidence, · severity, and 
duration of SCh-induced myalgia. Their results were similar to both of the above 
studies. They found in subjects receiving intraoperative SCh, only 16% of the 
subjects detailed postoperative myalgia with muscular pain after pretreatment, as 
opposed to 60% experiencing pain without pretreatment. Although serum 
potassium and CPK levels were not measured in this study, the outcome 
remained the same. These authors suggested that pretreatment with diazepam 
should be considered for decreasing postoperative myalgia in subjects receiving 
SCh. 
Chestnut, Lowry, Dundee, Panditt, and Mirakhur (1985), however, failed to 
confirm the above detailed findings. In a comparison trial of diazepam, 
midazolam, and DTC, these authors concluded that -postoperative myalgia was 
not prevented by any of the benzodiazepine pretreatments. Interestingly enough, 
the DTC group had less reported myalgia than the other groups. Additionally, 
unlike the previous three studies, electrolyte and biochemical changes in these 
authors' study subjects were found to be inconsistent among all groups. 
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The unpredictable and inconsistent findings of the above detailed studies 
cause this author to conclude that biochemical and electrolyte changes after the 
administration of SCh may not have an association with postoperative myalgia. 
Additional support for this notion is provided by the study of Mcloughlin, Elliot, 
McCarthy, & Mirakhur (1992). Although their pretreatment was not diazepam, but 
rather a variety of other medications, they reported that there was no correlation 
between myalgia and rises of CPK. Therefore, they concluded that biochemical 
changes and postoperative myalgia were separate and distinct entities. 
Ch/orpromazine 
Mcloughlin, Elliot, McCarthy, and Mirakhur (1992) provided some evidence 
that chlorpromazine was effective in preventing postoperative myalgia. It is 
thought that chlorpromazine inhibits phospholipase A2, a major enzyme, which is 
ultimately responsible for the release of fatty acids. It has been postulated that 
such release causes muscle damage, in turn causing postoperative myalgia. 
Therefore, inhibition of this enzyme should prevent such damage and its 
resultant myalgia. This concept was confirmed by their study. They found rises 
in CPK, serum potassium, and serum calcium insignificant when chlorpromazine 
was used as a pretreatment, indicating the preservation of muscle function. 
Additionally, only 15% of the chlorpromazine treated subjects reported having 
postoperative pain. Although Mcloughlin and associates reported that the use of 
chlorpromazine should be further studied, Wong and Chung (2000) discourage 
its use, noting the side-effect profile of chlorpromazine would outweigh the 
benefits for its use in the prevention of postoperative myalgia. 
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Aspirin/Nonsteroidal Anti-Inflammatory Drugs 
As some of the above studies indicated, fasciculation results in muscular 
damage and the release of CPK, myoglobin, and electrolyte disturbances. Work 
performed by Kahraman, Ercan, Aypar, and Erdem (1993) found elevations of 
enkephalins, prostaglandins, leukotrienes, and histamines in subjects that 
fasciculated. Such chemicals are major causes of nociception and start the 
cascade of events that fit into the framework of the gate control theory of pain 
(Sackett & Cannon, 1999). Prostaglandins not only sensitize pain receptors, but 
also potentiate the actions of histamine and bradykinins. Thus, the substances 
allow for increased pain modulation and perception by the patient. 
Kahraman and associates hypothesized that by inhibiting prostaglandins 
perhaps postoperative myalgia could be decreased. Their study involved 34 
healthy subjects undergoing elective ophthalmic surgery. Preoperatively each 
subject within the treatment group received oral diclofenac, a nonsteroidal anti­
inflammatory (NSAID), prior to the administration of SCh. They reported a 30% 
reduction of postoperative myalgia in this experimental group, as compared to 
the untreated group. Although these authors found no correlation be�een 
myalgia and the severity of fasciculation, they concluded preoperative 
administration of diclofenac nonetheless reduced postoperative myalgia. 
Previous work performed by Mcloughlin, Nesbitt, and Howe (1988) found 
similar results with the preoperative administration of oral aspirin. They identified 
a 36% reduction in postoperative myalgia among those subjects who were 
treated preoperatively with aspirin. These results, like those of other 
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investigators discussed in the following section, were once again attributed to the 
inhibition of prostaglandin synthesis. As previously noted, interrupting the 
cascading events of the gate control theory, resulting in decreased pain 
modulation and ultimately diminished pain perception . . 
More recent studies using ketrolac (a NSAID), by Leeson-Payne, Nicoll, and 
Hobbs (1994), did not support the findings of the previous two studies. They 
enrolled 60 healthy subjects within their study and administered intravenous 
ketrolac preoperatively. As mentioned, they concluded that ketrolac did not 
significantly prevent postoperative myalgia in subjects receiving SCh 
perioperatively. Their results were unexpected findings, since ketrolac is 350 
times more potent in the inhibition of prostaglandins than aspirin. It is of 
importance to note that just as intravenous dantrolene did not have the same 
result as the oral form, here too a similar observation has been made with the 
use of NSAIDS. Again, this topic has been identified as an area for needed 
future study. Specifically, the question needing investigation is whether the oral 
form of ketrolac would show a difference from the intravenous form, with respect 
to postoperative myalgia in subjects receiving SCh in the perioperative period. 
Phenytoin 
Hartmen, Fiamengo, and Riker (1986) demonstrated that phenytoin 
prevents fasciculation by a prejunctional mechanism. However, this study was 
performed in vitro, and despite such findings, these results have not been 
replicated in humans. In fact, Hatta, Saxena, and Kaul (1992) not only found that 
there was no relation in the incidence of fasciculation, but there also was no 
31 
relationship/correlation among fasciculation, serum potassium levels, and 
postoperative myalgia when phenytoin was used as a pretreatment. Although 
phenytoin did not significantly prevent fasciculation or changes in serum 
potassium, they concluded that it significantly reduced postoperative myalgia by 
as much as 18.3%. They postulated that such a finding was caused by the 
stabilization of motor nerve terminals. As with calcium gluconate, there are 
relatively few studies using phenytoin as a pretreatment for postoperative 
myalgia. Therefore, much more research is indicated before we make changes in 
our current methods or practices with regards to phenytoin usage for the 
reduction of SCh related postoperative myalgia. 
Nondepolarizing Agents 
Since Churchill-Davidson's finding in 1954, that pretreatment of subjects with 
gallamine significantly reduced postoperative myalgia, numerous studies have 
been performed to assess the effectiveness of varying nondepolarizing agents on 
this phenomenon. Although the exact mechanism is not fully understood, the 
use of nondepolarizing neuromuscular blocking agents is currently the most 
widely accepted practice for treatment and prevention of postoperative myalgia in 
individuals who are to have SCh as part of their anesthetic plan (Deehan, 
Henderson, & Stewart, 2000). For purposes of this author's review, 10 studies 
will be examined in order to provide increased insight to this enigmatic 
pretreatment for the prevention of postoperative myalgia in conjunction with SCh 
usage. 
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Because they were the first nondepolarizing agents available, gallamine and 
DTC are the two most studied medications within the literature, which have been 
used for the pretreatment of fascicul�tion and prevention of postoperative 
myalgia. However, DTC is no longer commercially available due to agricultural 
and manufacturing constraints. Although the literature is suggestive that DTC 
prevented fasciculation better than any current modern nondepolarizing agents, 
this drug will no� be a focus of this study since it is no longer commercially 
available (Pinchak, Smith, Shepard, & Patterson, 1994). Sadly, it is anticipated 
that this drug will never commercially resurface in the world of anesthesia again. 
After Churchill-Davidson's original work, no less than_ six additional 
researchers performed studies utilizing gallamine in the pretreatment of 
postoperative myalgia in conjunction with SCh administration. Glauber (1966) 
found that pretreatment significantly reduced postoperative myalgia in female 
subjects, from 4 7 .2% without pretreatment, to 16% with pretreatment. The same 
phenomena did not occur among the male subjects in his study. Male subjects 
reported a 48.4% incidence of experiencing pain without pretreatment, and 
36.4% with pretreatment. Glauber made an interesting find through his work, 
however, that remains important for modern day research in this subject area. 
The pretreatment of DTC in his study was given as a single dose of 5 mg. It was 
not based on body weight. Therefore, it could be concluded that pretreatment in 
males did not reveal any statistical significance because the dose was not large 
enough to counteract the effects of SCh in the heavier and more fully muscled 
male subjects. This author believes that pretreatments should be based on 
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mg/kg basis for any degree of scientific significance to be ascertained from study 
results. 
Brodsky, Brock-Utne, and Samuels (1 979) were the first to investigate the use 
of pancuronium as a pretreatment for SCh-induced postoperative myalgia. They 
used two groups that were identical with respect to age, weight, anesthetic 
technique, and length of operation. Group one was pretreated with pancuronium, 
while group two did not have any pretreatment. Ninety-five percent of subjects 
within group two had fasciculation, while only 20% of group one exhibited 
movement. Statistically, pancuronium made a difference in fasciculation. 
However, in terms of postoperative myalgia, neither group had impressive 
findings. Although those pretreated with pancuronium did have less myalgia 
(20%), the measured difference was not significantly different from those who did 
not receive pretreatment (35%) . Therefore, Brodsky and associates (1 979) 
concluded that there was no correlation between fasciculation and postoperative 
myalgia. Additionally, they stated that pancuronium "does not decrease the 
incidence or severity of postoperative myalgia . . . " (p. 261 ) .  
O'Sullivan, Williams, and Calvey ( 1 988) performed a comparison study of 
pretreatment doses of gal lamine, pancuronium, and taming doses of SCh. Their 
findings were in agreement with many previous studies, in that gal lamine 
inhibited fasciculation better than pancuronium. Additional ly, they concluded that 
there was not an association between fasciculation and postoperative myalgia. 
However, in regards to postoperative myalgia, they found just the opposite from 
the previous study. Pancuronium had a greater effect on postoperative myalgia, 
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and significantly reduced postoperative pain better than gallamine. Ultimately, 
they reasoned that gallamine acts at the prejunctional site to decrease the rate of 
firing, and therefore decreases fasciculation. Pancuronium, on the other hand, 
was postulated to work at the postsynaptic site and decreases postoperative 
myalgia. Therefore, providing reasoning for what others have hypothesized 
throughout the literature, that fasciculation and postoperative myalgia are caused 
by different mechanisms. 
Although varying results have been do_cumented throughout the literature, 
atracurium is currently one of the most studied and most effective 
nondepolarizing agents for the prevention of postoperative myalgia (Pace, 1 990). 
Perhaps this is because it is metabolized by Hoffman elimination in addition to 
being eliminated through ester hydrolysis, and therefore can be safely used for 
even the sickest of subjects who may have hepatic and renal dysfunction. This 
safety index is one reason why atracurium was chosen as the focus of this study. 
The following section reviews several studies found within the body of literature 
comparing atracurium to other nondepolarizing agents and their effectiveness in 
reducing postoperative myalgia. 
Sosis, Broad, Larijani, and Marr (1 987) compared atracurium, normal saline, 
and DTC and measured for both fasciculation and postoperative myalgia in 
subjects receiving SCh. They found that OTC prevented fasciculations better 
than atracurium, but the reverse was true for postoperative myalgia. Although 
the only significant finding was that both OTC and atracurium significantly 
decreased postoperative myalgia when compared to saline, neither was 
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significantly superior to the other. However, numerically, there is a 26% 
difference between the two groups. Eighty-five percent of subjects pretreated 
with atracurium were free from postoperative pain, while only 59% of subjects 
treated with OTC reported the absence of postoperative myalgias. 
Hochhalter (1996) found just the opposite of Sosis and associates. This 
studies results indicated that atracurium, when compared to normal saline, 
decreased fasciculation, but had little effect on postoperative myalgia in subjects 
who received SCh. Additionally, Hochhalter concluded that there was no relation 
between fasciculation and postoperative myalgia, as several subjects were 
recorded as having very defining fasciculations, but no muscle soreness. 
Although atracurium was effective in preventing fasciculation (73%), the 
incidence of postoperative myalgia was not prevented, with 1 2% of the 
pretreatment group having pain. Although this does not sound like much of a 
difference when compared to other studies, this is a large dissimilarity 
considering there was only a rate of 33% overall reporting pain during the first 24 
hours. 
Martin, Carrier, Pirlet, Claprood, and Tetraults' (1 998) study compared the 
following agents: normal saline (control), OTC, vecuronium, atracurium, 
rocuronium, and mivacurium. They observed the usual finding of 50% 
postoperative myalgia within the normal saline group. However, myalgia was not 
significantly diminished by any of the pretreatments. In terms of postoperative 
myalgia, they concluded that there was not any advantage to pretreatment. In 
fact, they noted that pretreatment could even be potentially dangerous, in that the 
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mivacurium group not only resulted in the need for a larger dose of SCh, but also 
resulted in a prolonged paralytic block. 
Tsui , Reid, Gupta, Kearney, Mayson and Finucane (1 998) compared 
atracurium, rocuronium and normal saline. Unlike previous studies, they found 
evidence that rocuronium significantly reduced both fasciculation and 
postoperative myalgia in subjects who received SCh as a component of their 
general anesthetic. Although atracurium was found to reduce postoperative 
myalgia, it was not until postoperative day number two that this finding became 
significant. Therefore, it was concluded that rocuronium was a better choice for 
the pretreatment of both fasciculation and postoperative myalgia than atracurium. 
Previous work performed by Demers-Pelltier, Drolet, Girard, and Donati 
(1 997) found similar results to Tsiu and associates. Their work compared 
rocuronium, OTC, and normal saline in subjects who also received SCh. They 
concluded that rocuronium and OTC were equivalent in preventing fasciculations. 
However, like Tsui and associates,  they found that rocuronium significantly 
decreased postoperative myalgia over OTC . . Like many previous studies, this 
investigation demonstrated that pretreatment with a nondepolarizing agent 
delayed the onset of SCh and shortened the duration of the block. In this case, 
rocuronium had much more of an enhanced affect than did OTC. In order to 
prevent such a problem, higher doses of SCh would be needed. As previously 
mentioned, this discovery opened inquiry to an additional confounding variable, 
one that had not been anticipated prior to its identification. Did the increased 
dose of SCh affect the degree or amount of postoperative myalgia? 
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Because of varying results among studies comparing differing agents, it has 
been suggested and demonstrated that combination therapy appears to be the 
most useful method in preventing postoperative myalgia (Wong & Chung, 2000). 
Until the exact mechanism of myalgia is determined, attacking investigation of 
this subject at differing angles may be the best approach. Melnick, Chalasani, 
Uy, Phitayakorn, Mallett, and Rudy ( 1987) found that OTC in combination with 
lidocaine provided subjects who received SCh with less postoperative myalgia 
than either medication used separately. The incidence of pain in the combination 
group was only 8.3%. This was 30% less than the incidence reported in any of 
the other groups. Their results, therefore, lead many authorities in this area of 
investigation to the conclusion that combination therapy improves patient 
outcomes in terms of postoperative SCh-induced myalgia. 
Raman and San ( 1997) also found combination therapy to be effective in 
reducing myalgias. Their study established that subjects pretreated with both 
atracurium and lidocaine had a significantly lower incidence of postoperative 
myalgia following SCh administration than those pretreated with each medication 
separately. The control group had a 75% incidence, atracurium had a 35% 
incidence, lidocaine had a 30% incidence, and the combination group only had a 
5% incidence of postoperative myalgia. These findjngs support utilizing two lines 
of attack, as lidocaine works as a cell membrane stabilizer. Although different 
studies have demonstrated differing results, atracurium is thought by most to be 
active at prejunctional sites (Wong & Chung, 2000). 
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Although many facts about SCh have been known since 1 960, only 1 0  years 
after the first routine use during general anesthesia, the definitive cause of 
postoperative myalgia remains unidentified . Foster quoted the following passage 
from a 1960 journal article (p. 25) : 
Every time suxamethonium [succinylcholine] is used consideration must 
be g iven to the indications for its use and the incidence of muscle pains 
afterwards, and we must all hope that the chemists wi ll produce a new 
relaxant with the advantages of suxamethonium [succinylcholine] but 
without its capacity for producing these pains. 
How ironic, that nearly half a century later, we continue searching for the same 
answers to questions that first were documented in 1 960. 
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Chapter I l l  
Materials and Methods 
The overall purpose of this pilot study was to discover the feasibility and 
practicality of subsequently implementing a ful l-scale study aimed at identifying 
the best medication or combinations of medications that reduce postoperative 
myalgia fol lowing the administration of SCh when it is utilized as part of a general 
anesthetic. This pilot study examined and compared the efficacy of pretreatment 
with atracurium, lidocaine, or the combination of these two medications in relation 
to the reported incidence of postoperative myalgia in subjects who received SCh. 
The Postoperative Myalgia Survey (PMS) was utilized to collect data regarding 
muscle pain in subjects who had received SCh as a component of general 
anesthesia at 24, 48, and 72 hours postoperatively. This instrument is a 14-
question survey that not only allows subjects to describe their pain both 
quantitatively and qualitatively, but also allowed the researcher to distinguish 
whether the pain being experienced by the subject was truly myalgia, rather than 
some other type of related surgical discomfort. The researcher applied data 
gathered from the utilization of the PMS to a second instrument, known as the 
Postoperative Myalgia Evaluation Scale (PMES). 
The PMES is a modification of the Visual Analog Pain Scale (VAPS) and was 
used to rate and record the overall severity of the myalgia on a O - 3 Ukert scale, 
based on the occurrence and severity of myalgia as it was described by the 
subject. Because the focus of this study did not consider it adequate to only 
report myalgia experienced by t_he subject, which was collected by the PMS, the 
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PMES was employed to specify the incidence and severity of the reported 
myalgia as it related to each of the three study groups. 
Throughout the remainder of this chapter, this author will explore and present 
operational definitions, the research design·, subject sample and setting, inclusion 
and exclusion criteria, informed consent, study protocol, instrumentation, data 
analysis, assumptions, study limitations, specific risks and protection measures, 
and potential benefits as they relate to the pilot study. 
Operational Definitions 
As it is essential for all readers of this manuscript to assure consistent 
understanding of some pivotal terminology, the following section lists the 
operational definitions that should be used throughout the remainder of this 
paper. 
1. American Society of Anesthesiologists (ASA} - The American Society of 
Anesthesiologists is an educational, research and scientific association of 
physician anesthesiologists who have organized to raise and maintain the 
standards of the medical practice of anesthesiology and improve the care 
of the patient. 
2. ASA Physical Status Classification (PSC) I and/or ASA PSC I I  -
Describes the physical status of a patient at the time· of surgery. 
Appendix A holds specific definitions. 
3. Endotracheal Anesthesia - General anesthesia that is delivered to the 
lungs through the trachea via an endotracheal tube. 
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4. Endotracheal tube - A large tube that is inserted through the nose or 
mouth into the trachea, by which oxygen, anesthetic gases, and/or 
volatile anesthetics are delivered. 
5. Laparoscopic Surgery - Intra-abdominal surgery performed through small 
incisions with the use of laparoscopic instruments. These are surgical 
instruments that include a camera that transmits the image inside the 
body cavity by allowing the surgeon to guide the surgical instruments and 
perform the procedure. 
6. Neuromuscular iunction - The area between the ends of myelinated nerve 
fibers and it's corresponding skeletal muscle. 
7. Outpatient - A non-hospitalized patient who receives same day medical 
treatment, is discharged less than 24 hours following admission, and then 
returns home for convalescence. 
8. Postoperative myalgia - muscle soreness that occurs after surgery. It is 
best described as the feeling one gets after a period of aggressive, 
physical exercise. 
Research Design, Sample, and Setting 
After approval was obtained from the lnvestigational Review Board (IRB) 
committees at the University of Tennessee Medical Center-Knoxvil le and the 
University of Tennessee in Knoxville, this prospective, randomized, double-blind 
study was carried out as a pilot study on 15 subjects who met the requirements 
of the ASA PSC I and/or ASA PSC II (Appendix A). The convenience sample 
was selected from all adult outpatients who were listed on the daily surgical 
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schedule for laparoscopic surgery at a Level I Adult and Pediatric Trauma Center 
in the Southeast United States. The entire investigation took place on 2-North in 
the main operating room surgical suites. 
Inclusion and Exclusion Criteria 
All subjects met the fol lowing inclusion criteria in order to be enrolled in the 
study. These criteria included the fol lowing: 
1 .  Subjects between 1 8  - 50 years of age, as postoperative myalgia is 
shown to be most prominent in this age group. 
2. Subjects requiring elective, outpatient laparoscopic surgery under general 
endotracheal anesthesia, as this helped to eliminate surgical incisional 
pain. 
3. Subjects with a body mass index (BMI) between 1 8  - 30, as subjects less 
than 1 8  may have experienced weakness from a pretreatment dose of 
nondepolarizing agent (atracurium). 
4. ASA PSC of I or I I, as sickly subjects (ASA PCS's > I I) have increased 
reasons to experience postoperative myalgia. 
5. Ambulatory ( outpatient) subjects only, as these subjects would have been 
expected to exhibit the most postoperative myalgia. 
Subjects were assessed to determine if any exclusion criteria applied to them. 
If so, they were not enrolled in the study. Exclusion criteria included the 
following: 
1 .  Subjects not meeting inclusion criteria as described above. 
2. Subjects' known to be pregnant, as it has been shown that pregnancy 
decreases the incidence of postoperative myalgia. 
3. Subjects with co-existing disease states, as they would have fallen into an 
ASA PSC level of greater than II. 
4. Subjects who were non-ambulatory, bedridden, or wheelchair bound, as 
SCh may have been contraindicated. 
5. Subjects who experience shivering upon emergence, as this alone could 
have caused postoperative myalgia. 
6. Subjects who did not have access to a telephone, as follow up calls would 
have not been possible. 
7. Subjects younger than 18, as informed consent would have been a 
parental decision. 
8. Subjects older than 50, as $Ch-induced myalgias are reported less 
commonly in this group. 
9. Subjects allergic to any of the study medications, or medications 
employed in the standard study plan (Appendix B). 
10. Subjects with any conditions that would be contraindicated by the 
administration of any drug within the standard plan (e.g. Malignant 
Hyperthermia, neuromuscular disorders, or myofascial pain syndromes). 
11. Any subject who was unable to give full voluntary and informed consent. 
12.Any subject who received narcotic reversals, such as narcan. 
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Informed Consent 
Informed consent (Appendix C) was obtained upon completion of the 
preoperative interview and determination that the subject met inclusion criteria. 
The use of this consent had been approved by the IRB's of both the University of 
Tennessee Medical Center-Knoxville, and the University of Tennessee, Knoxville 
prior to the initiation of the study (Appendix D). The study �as explained in terms 
understandable to the subject, and the subject was given sufficient time to 
consider participation prior to providing consent. Subjects were ensured that 
they would not be treated differently, regardless of their decision concerning 
participation. Those who agreed to participate in the study were informed that, if 
at anytime they would better be served by being withdrawn from the study, the 
researcher would do so immediately and continue to provide any and all 
intervention that was required to safely care for them. 
Study Protocol 
Preoperatively, all subjects were premedicated with midazolam 0.025 mg/kg 
and an appropriate antibiotic as requested by the surgeon. Subjects were 
assigned by pharmacy to one of the following three double-blinded study groups 
by use of computer generated randomization. 
1. Group A was pretreated with atracurium 0.05 mg/kg intravenously (IV) 
prior to the administration of 1.5 mg/kg IV of SCh. 
2. Group B received 1.5 mg/kg of lidocaine prior to the administration of 1.5 
mg/kg of SCh. 
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3. Group C received both pretreatment medications at the above indicated 
doses prior to the administration of 1.5 mg/kg IV of SCh. 
It was decided by the researcher to avoid a control group since many studies 
indicate that a 50% incidence of postoperative myalgia can be expected from 
the administration of SCh. In addition, although the literature was not clear on 
the effectiveness of pretreatment when SCh is utilized, depriving subjects of a 
medication that might be of benefit by reducing postoperative discomfort was 
not ethically acceptable to this author. 
The following study protocol was utilized on all groups: 
1. After the researcher obtained informed consent, the subject was 
transported to the operating room and positioned on the operating table 
appropriately for the surgical procedure. 
2. Standard ASA monitoring was utilized (Appendix E). 
3. Pre-oxygenation was obtained with 100% oxygen for 2 minutes or 5 vital 
capacity breaths. 
4. The pretreatment drug was given along with fentanyl 1.5 mcg/kg. (This 
dose of fentanyl was given to blunt stimulation from laryngoscopy and 
has not been demonstrated to affect myalgias in previous investigations). 
5. Five minutes after the administration of the pretreatment drug an 
appropriate induction dose of propofol (2-2.5 mg/kg IV) was given for 
induction. 
6. After complete muscle relaxation was verified, (0/4 twitches following 
ulnar nerve stimulation via cutaneous electrodes), tracheal intubation was 
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performed and endotracheal tube placement was verified by standard 
methods. 
7. Anesthesia was maintained with oxygen, and air or nitrous oxide, and by 
titrating sevoflurane 0.6%-5% to hemodynamic stability and a surgical 
level of anesthesia. The Bispectral Index (BIS) monitor was utilized as an 
adjunctive monitor to help assess the subject's level of anesthetic depth. 
8. If the subject's blood pressure and heart rate fluctuated (Appendix F) 
(increased or decreased) greater than 20% of base line, then 
vasodilators, vasopressors, inotropes, or chronotropes were administered 
as appropriate for the situation. If the subject failed to respond, they were 
eliminated from this study and further appropriate treatment was 
instituted. 
9. The following drugs were administered as their need arose: narcotics, 
(fentanyl 2-10 mcg/kg), nondepolarizing muscle relaxants, antiemetics, 
steroids, antibiotics, vasoactive drugs, and muscle relaxant reversals. 
These medications were not part of the study protocol, but are routinely 
employed in the anesthetized patient. (See Appendix B for this study's 
formulary doses and adverse effects of drugs). 
10. After completion of the surgery, anesthesia was discontinued. The 
subject was given 100% oxygen to breathe. They were extubated when 
extubation criteria were met (Appendix G). Following extubation, the 
subject was taken to the post-anesthesia recovery room. If the subject's 
nurse observed any postoperative shivering, it was documented on the 
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PMES in Appendix H. (Such subjects were withdrawn from the study, as 
shivering has been shown to cause myalgias). 
1 1 . All subjects were contacted 24, 48, and 72 hours postoperatively by 
telephone and asked the questions listed on the PMS (Appendix I). The 
researcher then rated and recorded the level of myalgias using the PMES 
(Appendix H). 
As described, pre-treatment medications in all three groups were 
administered to subjects using a double-blind format. The surgical pharmacy 
randomly assigned subjects to one of the three study groups by computerized, 
random selection. Syringes of study medications were labeled with numbers 
(from 1 -1 5) by the pharmacy staff for each patient enrolled in the study. The 
pharmacy was the only provider who knew which patient received which study 
medication prior to completion of the study. The pharmacy staff was instructed 
to disclose this information if and only when the following occurred: 
1 .  All data had been collected. 
2. The study was complete or it was closed. 
3. Lastly, in the case that it became necessary to know what medications 
had been given, as in the case of an allergic reaction. 
Every pretreatment medication came in a syringe that contained the same 
volume amount, regardless of the exact medication. This was done so the 
researcher in no way could identify which pretreatment medication was given. 
Dosages of all medications were calculated based on per kg of body weight by 
the pharmacy prior to anesthetic administration. At the end of the study, the 
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drugs were identified to conclude whether there was a difference between the 
pretreatment groups with respect to comparison of one another. The same 
researcher was used to gather all postoperative information regarding myalgia. 
This data was analyzed after the completion of data collection. 
All subjects were assigned a number once enrolled in the study. Subjects 
were sequentially numbered 1-15. A Demographic Data Sheet (See Appendix 
J), served as the master enrollment list, and was maintained on all subjects who 
agreed to participate in the study. This data sheet contained the following 
information: 
1. Name 
2. Phone Number 
3. Subject number ( 1-15) 
4. ASA Class 
5. Weight in Kg 
6. Height in inches 
7. Gender 
8.  Smoking history 
9. Preoperative narcotic and NASID use (dose and duration) 
10. Postoperative narcotic and NASID use (dose & duration) 
For reasons related to postoperative data collection, it was necessary to 
maintain the subject's name and telephone number. However, subjects were 
not to be identified by any method other than on the Demographic Data Sheet, 
unless it became necessary for the safety of the subject as in the case of an 
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allergic reaction or unstable hemodynamics. As mentioned previously, such 
subjects would have been removed from the study. In these instances, the 
double-blinded protocol medication would have been revealed so as to provide 
the most appropriate and prompt intervention possible. 
Instrumentation 
The PMS (Appendix I) is a tool that was utilized by the researcher to confirm 
the patient was experiencing postoperative myalgia, as opposed to some other 
type of postoperative surgical discomfort. The PMS is a 14-question survey that 
determines the type, location, and amount of pain being experienced. 
Additionally, it inquired about the subject's activity level, as well as any 
treatments they attempted to help alleviate the muscular soreness. This survey 
has only been utilized in one previous study, which was discovered in the body 
of associated literature: The works of Mikat-Stevens, Sukhani, Pappas, Fluder, 
Kleinman, and Stevens (2000). Therefore, the PMS has no proven validity or 
reliability. Its use in this study is being justified by the fol lowing reasoning. 
Many past studies on the subject of SCh use and postoperative myalgia have 
fai led to carefully distinguish between myalgia and surgical discomfort. The 
PMS aids the investigator in establishing this distinction, which was considered 
by this author to be of fundamental significance to the purpose of this 
investigation. Utilizing two tools within this study helped to assure, with greater 
confidence, that proper assessment of the type of postoperative pain was 
distinguished allowing for the overall study results to be truly reflective of 
postoperative myalgia as it related to perioperative SCh administration. 
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The PMES (Appendix H) is a four-point ordinal scale that measures the 
severity of postoperative myalgia from zero to three, where [O] indicates 
absence of pain other than characteristic surgical gas, [1] indicates mild muscle 
stiffness or pains, when specifically asked about, in the nape of the neck, or in 
shoulders and lower chest on deep breathing, [2] indicates moderate muscle 
stiffness and pains spontaneously complained of by the patient [3] indicates 
severe, incapacitating, generalized muscle stiffness or pain. Although the 
PMES, or very similar scale, has been used in several previous studies of 
comparable nature and scope as this one, this scale had no proven reliability or 
validity. However, numerous respected scientists have accepted this instrument 
as a valid and reliable measure of postoperative myalgia in subjects following 
the administration of SCh with general anesthesia. These same authors have 
utilized this instrument for the purpose it was used in this author's investigation. 
Such studies have had similar scope and intent as the current one (Mingus, 
Herlich, & Eisenkraft, 1990; Mcloughlin, Elliot, McCarthy, Mirakhur, 1992; 
Raman & San, 1 997). All such, authors have been published in a variety of 
respected and refereed scientific medical journals including: Anaesthesia and 
the Canadian Journal of Anaesthesia. Consequently, since there were no 
alternative tools that existed which had a proven higher index of validity or 
reliability, this author chose to utilize these two tools in the current study in 
hopes of obtaining a more accurate picture of the phenomena of postoperative 
myalgia in relation to SCh administration. The goal of using these two tools was 
to accurately measure the occurrence and severity of postoperative myalgia 
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following SCh administration subsequent to the pretreatment of atracurium, 
lidocaine, or the combination of the two. Since it was important to maintain 
consistency and provide reliable measurements of postoperative myalgia, the 
same researcher administered the survey and rated the severity of soreness to 
study subjects for up to 72 hours postoperatively (See protocol #11 ). 
Data Analysis 
Comparison of the mean scores of the three study groups would traditionally 
have been performed by analysis of variance (ANOVA) utilizing parametric 
testing. However, this statistical application would have required a specific 
distribution of the mean and variance. Testing of the PMES lies within a gray 
area, and such, a distribution could not be assumed. Therefore, a 
nonparametric AN OVA with post-hoc analysis was employed. Specifically, the 
Kruskal-Wallis, a test for two or more independent samples, and the Bonferroni 
test utilizing a significance level of p<=0.05 was employed. 
The Kruskal-Wallis test calculates results based on the sums of the ranks of 
the combined groups in the PMES. For example, the scores for each variable 
(0, 1, 2, 3) was ranked, and the mean ranks for the variables were compared. If 
a significant difference was found (p<= 0.05) a post-hoc analysis utilizing the 
Bonferroni method was planned to be employed to identify where the difference 
occurred. Because this method is more sensitive in small comparisons, it was 
utilized in this pilot study of 15 subjects. Such methods were utilized not only to 
determine which pretreatment medication(s) were significantly effective in 
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reducing postoperative myalgia, but also to determine which postoperative day 
subjects experienced the most/least myalgia. 
Assumptions 
The basic assumptions made regarding this study were as follows: 
1. The PMS and PMES were predictive and accurate instruments for 
measuring postoperative myalgia. 
2. The population sample was representative of a random sample. 
3. The researcher was consistent at determining if the pain was myalgia 
verses surgical discomfort. 
4. The researcher consistently rated the postoperative myalgia as described 
by the patient in the PMES. 
Study Limitations 
1. The review of the literature may not have been wholly reflective of reality. 
2. There may have been unanticipated individual varying responses to the 
prescribed anesthetic plan. 
3. There may have been sources of error concerning myalgia during data 
collection. However, this study attempted to take this into account by: 
(A) utilizing two tools that had been used significantly within the 
anesthesia literature, and (B) having the same researcher gather/rate the 
levels of myalgia. 
4. In regards to conclusions, to using the pretreatment medications of 
atracurium, lidocaine, or a combination of medications may not be able to 
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be generalizable to larger populations because of this pilot study's small 
sample size. 
5. Because the average incidence of SCh-induced postoperative myalgia is 
only 50% according to the literature, the benefits of a control group may 
have been useful for comparison. 
6. Neither the PMS nor PMES being utilized to measure postoperative 
myalgia has undergone extensive psychometric testing for validity or. 
reliability. 
7. This study made no attempt to control for the amount or type of 
medications that were prescribed and utilized by the subject 
preoperatively. Data on subject use of medications preoperatively, 
however, was collected. 
Specific Risks and Protection Measures for Human Subjects 
All medications utilized for this study have side effects that could have 
caused adverse reactions (Appendix 8). Although rare, some possible side 
effects that could have occurred included nausea, vomiting, sedation, prolonged 
muscle weakness, high potassium, increased body temperature, and seizures. 
Such reactions may have occurred in subjects receiving these drugs in the 
course of anesthesia regardless of whether or not the patient was participating 
in the study. Therefore, although there were associated risks to subjects in 
relation to their participation in this study, the potential for additional physical, 
psychological, social, legal, or other risks were estimated to be no greater than 
those compared to surgical subjects who did not enroll in this study and who 
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had received the same anesthetic medications and interventions commonly 
utilized in acceptable anesthetic practice. No drug or procedure in this study 
was proposed to be used in any manner that was outside of the normal 
anesthetic standard of care or acceptable patient care practice. Consequently, 
no additional amount of risk for injury was predicted for any subjects who agreed 
to participate in the study. 
Anonymity and confidentiality of data collected was indefinitely maintained. 
During the data collection phase, and at all times following this period, all data 
was under the direct supervision and control of the researcher, or an authorized 
assistant. Each subject was assigned a number (not the medical record or social 
security number), and other than the Demographic Data Sheet/Master Subject 
List (for purposes of follow up call and data col lection), no linkage between the 
subject and subject number was made. Storage of this information will be 
maintained in a locked area within the anesthesia department at the University of 
Tennessee Medical Center-Knoxvil le for a period of five years following the 
study. At the conclusion of this time period, the records wi l l  be destroyed by 
means of shredding. 
Although such patient data safeguards, as above, are included in the design 
of this study, patient data may be released through publication of research 
findings in such a fashion that subjects may be able to identify themselves with 
their data. This remote possibility is no greater for this study than any other 
research project. Lastly, upon postoperative follow-up at 24, 48, and 72 hours, 
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the PMS (Appendix I) was utilized to assure that no physical, psychological, or 
social damage occurred as a result of this study. 
Study Benefits 
In conclusion, there are currently no proven therapeutic alternatives to the 
treatment of postoperative myalgia. Many studies have undertaken the task to 
examine this concept. However, to date, study results have been inconclusive in 
yielding definitive results. Therefore, potential benefits of this study, which 
established the justification for conducting this investigation, included the 
following: 
1. A more comfortable recovery. 
2. Decreases in the loss of productivity through earlier return to preoperative 
level of functioning, with respect to the individual subject's baseline in 
activities of daily living related to decreased myalgia postoperatively. 
3. Fewer returns to the emergency room related to postoperative discomfort 
and concern over the source of discomfort. 
4.  The potential for a decreased need of postoperative pain medication. 
5. The potential for decreases in health care expenditures related to poor 
resource utilization. 
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Chapter IV 
Results 
This chapter presents the results of this author's pilot study, which was 
designed to compare the efficacy of atracurium, lidocaine, and the combination of 
the two therapies on the outcome of postoperative myalg ia following the 
administration of SCh during general anesthesia. The purpose of this 
investigation was not to document statistical significance in relation to 
premedication efficacy for such a small pilot population, but rather to determine 
the overall feasibility of conducting a larger study. Additionally, a secondary 
purpose of this pilot study was to look for trends within this population that might 
contribute to outcome and indicate clinical importance with need for further and 
future investigation. 
As this study has shown, besides the use of SCh, other influential factors can 
contribute to postoperative myalgia including ASA PSC, history of cigarette 
smoking, surgical position, the use of pre-surgical pain medications and surgical 
type. Therefore, the purpose of this chapter is two-fold: First to provide the 
outcome of differing pretreatment groups on postoperative myalgia, and second 
to offer descriptive statistics about the population, the above influential factors, 
and their interactions with the pretreatment groups. Through the use of these 
results, this author contends that further support and investigation is indeed 
justified and that the conduction of a larger study on SCh use and myalgia is 
warranted. 
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Descriptive Statistics 
The study population was comprised of 1 5  subjects undergoing elective 
laparoscopic surgery requiring general anesthesia with the use of SCh. Of the 
1 5  enrolled in the study, two were excluded. One subject was excluded due to a 
change in intraoperative procedure, and the other subject was excluded because 
of the unforeseen use of a laryngeal-tracheal anesthetic (L TA) that contained 
lidocaine. Use of this intervention could have potentially influenced the observed 
results and therefore altered the outcome of the study. Of the remaining 1 3  
subjects, gender distribution included 1 2  (92%) females and one male (8%) who 
ranged in age from 21  to 46, with a mean age of 33. All subjects were healthy 
with eight (62%) having an ASA PSC of I, and 5 (38%) being an ASA PSC of I I .  
Two subjects (1 5%) were smokers, and eight (62%) were taking nonsteroidal or 
narcotic medications for pain prior to surgical intervention. 
The 1 3  subjects were placed in one of three computer randomized 
pretreatment groups: (1 ) atracurium 0.05 mg/kg, (2) lidocaine 1 .5 mg/kg, (3) or 
a combination of atracurium 0.05 mg/kg and l idocaine 1 .5 mg/kg . Because past 
studies have indicated that there is a 50% incidence in SCh postoperative 
myalgia without any pretreatment, this author felt it unethical to include such a 
group for control (Wong & Chung, 2000). Therefore, since the main purpose of 
the study was to determine the feasibility of instituting the scientific investigation, 
�nd also whether these small pilot groups would follow the recurring trends that 
are found within today's research literature, lack of a control group was not of 
issue to this author or other investigators performing this study. 
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Pretreatment Group Efficacy 
After one of the researchers obtained subject consent, a hospital pharmacist 
was responsible for keeping track of the subjects computerized randomized 
classification, as well as compounding and preparing the correct study drug 
regimen for administration. As a result, the subjects were well distributed in the 
three pretreatment groups with five subjects (38%) in the atracurium group, four 
(31%) in the lidocaine group, and four (31%) in the combination atracurium and 
lidocaine group. In terms of pain intensity, the results from the subjects in each 
pretreatment group were then compared to one another each day (for a total of 
three days). This author utilized the Kruskal-Wallis test, a nonparametric version 
of the one-way analysis of variance for independent samples, which was 
calculated based on rank sums of the pretreatment groups for comparison 
between the pretreatment groups. It is important to note that intensity and the 
number of participants experiencing pain over the course of three days is 
different. Table 2 and Figure 2 describes and illustrates the percent of each 
group experiencing pain, while the rest of this section predominantly refers to 
intensity of pain. 
A comparison of the mean scores of intensity of pain for the first postoperative 
day is presented in Table 3 and illustrated in Figure 3. No significant difference 
was found between any of the pretreatment groups. In other words, statistically 
speaking, none of the pretreatment medications exhibited any increased ability to 
prevent postoperative myalgia when compared to the others. However, as 
61 
Table 2. 
Postoperative Myalgia: Percent of each Pretreatment Group per Day 
Atracurium 
Lidocaine 
Combination 
60 
50 
40 
30 
20 
1 0  
Figure 2. 
Day 1 
Day 1 
60% 
50% 
50% 
Day 2 
40% 
50% 
50% 
Day 2 Day 3 
Day 3 
20% 
50% 
50% 
'G:J Atracurium 
■ Lidocaine 
ISi Combination 
Postoperative Myalgia: Percent of each Pretreatment Group per Day 
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Table 3. 
Pain Comparison of Pretreatment Groups on Postoperative Day One 
Mean Standard Significance 
Deviation (Kruskal-Wallis) 
Atracurium 1 .20 1 .30 NS - 0.858 
Lidocaine 1 .00 1 . 15 NS - 0.858 
Combination .75 0.96 NS - 0.858 
* = Significant difference at the a = 0.05 level 
NS = Not Significant 
1 .2 
Age Range Mean 
Age 
32 - 46 41 
22 - 30 27 
21 - 41 31  
e Atracurium 
1 
0.8 
0.6 
0.4 
0.2 
------------4 
Mean Significance 
* = Significant difference at the a = 0.05 level 
Figure 3. 
■ Lidocaine 
� Combination I 
Pain Comparison of Pretreatment Groups on Postoperative Day One 
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mentioned above, the atracurium group was found to have the most 
postoperative myalgia on day 1 ,  with 60% of subjects having pain, followed by 
50% within both the lidocaine and combination groups. Although the same 
percentage of subjects complained of pain in the latter two groups, the 
combination group was found to have reported less intense pain scores 
regarding postoperative myalgia on day one, in comparison to the subjects in the 
atracurium and lidocaine group. This was a finding that is well supported within 
the literature (Raman & San, 1987). 
Table 4 and Figure 4 describes and illustrates the comparison of the mean 
scores for intensity of postoperative pain in the three pretreatment groups on 
postoperative day two. Like the first postoperative day, no significant difference 
was found among any of the pretreatment groups in regards to the intensity of 
reported postoperative myalgia. As above, although the number of subjects 
complaining of pain decreased from the first day, the atracurium group (40%) 
continued to experience the most intense postoperative pain. Although the 
lidocaine group remained at 50% of subjects experiencing pain, the intensity 
reported by these subjects was less than the subjects in the atracurium group. 
Lastly, in the combination lidocaine/atracurium group, 50% of subjects 
complaining of pain did not exhibit any decrease in the intensity of postoperative 
pain from day one. This was unlike the subjects in the atracurium and lidocaine 
groups. This was a surprising finding since this had not been reported in the 
literature (Melnick, Chalasani, Uy, Phitayakorn, Mallett, & Rudy, 
1987) . 
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Table 4. 
Pain Comparison of Pretreatment Groups on Postoperative Day Two 
Mean Standard Significance 
Deviation (Kruskal-Wallis) 
Atracurium 0.80 1. 10 NS - 1.000 
Lidocaine 0.75 0.96 NS -1.000 
Combination 0.75 0.96 NS-1.000 
* = Significant difference at the a = 0.05 level 
NS = Not Significant 
Mean Significance 
• = Significant difference at the a = 0.05 level 
Figure 4. 
Age Range Mean 
32 - 46 
22-30 
21 - 41 
Age 
41 
27 
31 
.� Atracurium 
I■ Lidocaine 
� Combination 
Pain Comparison of Pretreatment Groups on Postoperative Day Two 
65 
As described in Table 5 and illustrated in Figure 5, there was no significant 
differences in terms of intensity of postoperative myalgia demonstrated between 
the three pretreatment groups on postoperative day three. Although the 
atracurium group had started out with the most pain (60%) on day one, it had 
gradually decreased each consecutive day and actually ended up reporting the 
least amount (20%) of pain by postoperative day three. One subject, however, 
continued to experience pain on postoperative day number three, and reported 
the intensity of their pain as moderate. 
In terms of the amount of pain, 50% of the subjects in the lidocaine group, on 
day three reported the same amount of pain as the atracurium group in terms of 
intensity. Although this group started out reporting mid-range levels of pain 
intensity on day one (between atracurium and the combination group) and 
decreased slightly on day two, they did not improve by day three. Again, this 
was an interesting finding that is not congruent with the current literature of 
Melnick and associates. 
Additionally, as mentioned earlier in this chapter, the subjects in the 
combination group of atracurium and lidocaine started out reporting the least 
amount of intense pain. However, the scores reported by the subjects in this 
group on postoperative day two was exactly the same as on postoperative day 
one. Although, subjects within the combination group continued to improve in 
terms of pain intensity, they surprisingly reported pain scores that fell between 
the scores reported by the subjects in the atracurium and lidocaine groups on 
day three. This too, was a finding that differed from current literature. 
66 
Table 5. 
Pain Comparison of Pretreatment Groups on Postoperative Day Three 
Mean Standard 
Deviation 
Atracurium 0.40 0.89 
Lidocaine 0.75 0.96 
Combination 0.50 0.58 
* = Significant difference at the a = 0.05 level 
NS = Not Significant 
1 
0.8 
0.6 
0.4 
0.2 
0 
Mean Significance 
* = Significant difference at the a = 0. 05 level 
Figure 5 .  
Significance 
(Kruskal-Wallis) 
· NS-0.725 
NS-0.725 
NS-0.725 
Age Range 
32 - 46 
22 - 30 
21 - 41 
im Atracuriurn 
,■ Lidocaine 
ISi Combination 
Pain Comparison of Pretreatment Groups on Postoperative Day Three 
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Additionally, on day three the combination lidocaine/atracurium group continued 
to exhibit 50% of its subjects complaining of postoperative myalgia. 
ASA Physical Status Classification and Postoperative Myalgia 
As is evident from examining the results listed in Table 6 and illustrated in 
Figure 6, ASA PSC did not have a statistical significance on postoperative 
myalgia. This is not unexpected due to small sample size. However, some 
potentially interesting clinical aspects arise from comparing ASA PSC to 
postoperative myalgia. Within this pilot study, 62% of subjects were classified 
as ASA PSC I, while 38% were ASA PSC II. Of the eight subjects classified as 
ASA PSC I, three (37.5%) were in the atracurium group, four (50%) were in the 
lidocaine group, and one ( 12.5%) was in the combination group. Within the ASA 
PSC I group, three individuals (37.5%) complained of pain. The lidocaine group 
exhib ited the most pain during day one (50%), followed by the atracurium group 
(33% ). The combination lidocaine/atracurium group in this class (ASA PSC I) 
remained pain free on day one. Additionally, as an experienced anesthesia 
practitioner might anticipate for this collection of subjects, the lidocaine group 
reported the highest pain scores, with two individuals declaring their pain as 
moderate on the first postoperative day. 
On day two and three, only two subjects (25%) exhibited pain within this ASA 
PSC I sub classification. On both days, these were subjects from the lidocaine 
group and they rated their pain scores as mild and moderate. 
The ASA PSC II group contained five (38%) subjects. Four (80%) of these 
subjects complained of pain on the first postoperative day. This was a much 
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Table 6. 
ASA Physical Status Classification and Postoperative Myalgia 
ASA 
Day 1 
Pain 
0.41  
Significance Day 2 
(Kruskal-wa11is) pain 
NS 0. 15 
Significance Day 3 
(Kruskai-Wallis) pain 
NS 0.45 
• = Significant difference at the a = 0.05 level 
NS = Not Significant 
0.5 
0.4 
0.3 
0.2 
0.1 
Mean Significance 
• = Significant difference at the a = 0.05 level 
Figure 6. 
ASA Physical Status Classification and Postoperative Myalgia 
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Significance 
(Kruskal-Wallis) 
NS 
53 Atracurtum 
■ Lidocaine 
■ Combination 
higher incidence when compared to the ASA PSC I group, where only 37.5% 
reported pain. Additionally, the ASA PSC II group did not have any subjects in 
the lidocaine group. Therefore, comparisons between the pretreatment groups 
and ASA PCS I and II was limited since the ASA PSC II group did not contain 
any subjects in one of the pretreatment groups. This finding is interesting when 
one considers the fact that the lidocaine group reported the highest pain scores 
on all three days in the ASA PSC I group. Therefore, this leads this author to 
postulate that perhaps subjects classified as an ASA PSC II may have a higher 
incidence of postoperative myalgia when SCh is used in conjunction with a 
general anesthetic. 
When further examining this group (ASA PSC II), two subjects (40%) were in 
the atracurium group, while three subjects (60%) were in the combination group. 
All subjects (100%) complained of pain in the atracurium group with rated pain 
scores of moderate and severe on postoperative day one, while two subjects 
(67%) in the combination group complained of pain with ratings of mild to 
moderate. Following progression to postoperative day two, the amount and 
intensity of pain for the combination lidocaine/atracurium group remained the 
same on day two as reported on day one. The amount and intensity of pain 
scores for the atracurium group improved, as all subjects rated their pain as 
moderate. By day three, both groups had improved in amount and intensity of 
pain. The atracurium group had only one subject (50%) complaining of moderate 
pain and the two subjects (67%) within the combination atracurium/lidocaine 
group reported only mild pain ratings. 
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Smoking History and Postoperative Myalgia 
Of the 13 subjects, only two (15%) were smokers. Both subjects had 
significant smoking histories of one to two packs of cigarettes consumed per day 
for five years. Interestingly enough, postoperative pain studies revealed that 
these individuals had higher pain scores that lasted (and did not improve) for the 
duration of the third postoperative day. Table 7 and Figure 7 displays and 
illustrates this data. - In addition, further analysis revealed that each of these two 
subjects received the combination pretreatment. 
Recalling the pattern of this group (which started out reporting the least 
amount of intense pain, but increased to an average amount of intense pain) 
suggests that smoking may be an influential factor responsible for increasing 
postoperative pain in subjects wtio receive SCh. However, as the following data 
will show, further analysis also revealed other factors that may have contributed 
to this outcome: Lithotomy position during anesthesia, subjects self­
administering medications prior to surgical intervention, and the fact that both 
individuals had diagnostic laparoscopic procedures. 
Nonsmokers (85%) were members of all three pretreatment groups. They 
were found to demonstrate the general population trends that have been 
previously noted within each pretreatment group. The atracurium group had the 
most number of subjects and 60% of these subjects reported the most intense, 
severe pain on the fi rst postoperative day. The lidocaine group had a 50% 
incidence of moderate pain, and surprisingly, the combination group did not 
report any pain. 
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Table 7. 
Smokers and Nonsmokers: Postoperative Pain 
Day 1 
Mean pain 
score 
Nonsmoker 0.91 
Smoker 
1.6 
1.4 
1.2 
1 
0.8 
0.6 
Figure 7. 
1 .50 
· �--
�--�--
Day 1 
Standard Day 2 
Deviation Mean pain 
score 
1 . 1 4  0.64 
0.71 1 .50 
Day 2  Day 3 
Smokers and Nonsmokers: Postoperative Pain 
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Standard 
Deviation 
0.92 
0.71 
Day 3 Standard 
Mean pain Deviation 
score 
0.45 
1 .50 
0.82 
0.71 
■ Nonsmoker 
■ Smoker 
For postoperative days two and three, reported levels of pain in the atracurium 
group declined in frequency as well as intensity. 40% of the subjects reported 
with moderate pain and 20% of the subjects reported with mild pain. The 
lidocaine group (50%) continued to repeat the same frequency and intensity with 
mild and moderate pain reported on both days. Again, ironically, the combination 
atracurium/lidocaine group reported being free from pain for both days. 
Surgical Position 
This study involved the enrollment of subjects who were having surgical 
procedures that required they be placed in either the supine or the lithotomy 
position. Although not statistically significant, as indicated by Table 8 and 
illustrated by Figure 8, when subject position is broken down and evaluated 
separately it does appear to have some clinical significance in reference -to 
postoperative pain. Eight (61.5%) subjects were in lithotomy, while five subjects 
(38.5%) were in supine position. 
As Table 9 and Figure 9 demonstrate, those subjects in lithotomy position did 
experience more postoperative myalgia for all three days as compared to those 
subjects who remained in supine position. These findings lead this author to 
question if lithotomy position may have been a contributing factor to 
postoperative myalgia in these subjects. 
There were subjects enrolled in all three pretreatment groups who were 
placed in lithotomy or supine positions. However, when examining only subjects 
in the supine position, only one individual complained of pain for all three 
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Table 8. 
Surgical Position and Postoperative Myalgia 
Day 1 
Pain 
Position 0.28 
Significance Day 2 
(Kruskal-Wallace) Pain 
NS 0. 1 9  
Significance Day 3 
(Kruskal-Wallace) Pain 
NS 0.33 
* = Significant difference at the a = 0.05 level 
NS = Not Significant 
Day 1 Day 2  Day 3 
Figure 8. 
Surg ical Position and Postoperative Myalg ia 
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Significance 
(Kruskal-Wallace) 
NS 
I■ Position I 
Table 9. 
Surgical Position and Postoperative Myalgia: 
Position 
Lithotomy 
Supine 
1A 
1.2 
1 
0.8 
0.6 
OA 
0.2 
0 
Figure 9. 
Day 1 
Mean 
1 .38 
0.40 
Day 1 
Standard Day 2 
Deviation Mean 
1 .06 1 . 13 
0.89 0.20 
Day 2 Day 3 
Lithotomy and Supine 
Standard Day 3 
Deviation Mean 
0.99 0.63 
0.45 0.40 
Surgical Position and Postoperative Myalgia: Lithotomy and Supine 
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Standard 
Deviation 
0.74 
0.89 
■ Llthotorny 
l'.9 Suplne 
postoperative days. This subject was in the lidocaine only group and reported 
moderate pain on postoperative day one, mild pain on the second day 
postoperatively, and moderate pain by the third postoperative day. 
Of subjects who were positioned in lithotomy, patterns of postoperative pain 
somewhat followed the general trends as detailed previously in this chapter for 
the pretreatment groups. The atracurium group started out with the most 
subjects (75%) complaining of pain and subjects who complained of the greatest 
intensity of pain. Over the three days of postoperative data collection, subjects 
complaining of pain gradually decreased to 50% and 25% by days two and three 
respectively. Subjects reported pain intensity did not diminish over the three 
days of postoperative data collection. 
With respect to the number of subjects experiencing postoperative pain in the 
lithotomy position, study results indicated that the lidocaine only group ( 1 00%) 
and combination group (66%) reported similar discomfort for all three 
postoperative days. Both groups also reported the same pain intensity scores for 
the first two postoperative days, with lidocaine (1 subject) being moderate, and 
the combination group (3 subjects) being mild and moderate. By the third 
postoperative day, both groups also exhibited a decline in pain with lidocaine 
becoming mild, and the subjects in the combination group also reporting their 
pain as being only mild. 
Pain Medication use Prior to Surgical Intervention and Postoperative Myalgia 
Again, as indicated by Table 1 0  and Figure 1 0 , statistical significance between 
the use of medication and postoperative myalgia was not demonstrated 
76 
Table 10. 
Premedication and Postoperative Myalgia 
Day 1 
Pain 
Medication 0.84 
Significance Day 2 
(Krus1<a1-wa11is) Pain 
NS 0.61 
• = Significant difference at the a = 0.05 level 
NS = Not Significant 
" I■ 
• - 11 I 11 
-. ,. I 
Day 1 
Figure 10. 
Day 2 Day 3 
Premedication and Postoperative Myalgia 
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Significance Day 3 Significance 
(Kruskal-Wallis) Pain (Kruskal-Wallis) 
NS 0.20 NS 
I■ Medication I 
due to small sample size. However, when analyzing this group independently, 
there does appear to be at least some cl inical significance. Fifty-four percent (7 
subjects) were taking some type of pain med ication (either nonsteroidal or 
narcotics) prior to surgical intervention . 
As Table 1 1  and Figure 1 1  wil l  ind icate, these individuals reported higher 
postoperative pain scores for all three days, than d id those who were not taking 
any type of pain medication preoperatively . Additionally, subjects who did not 
report preoperative pain medication use required less postoperative pain 
medication as compared to subjects who reported taking pain medications 
preoperatively. Although the data was not col lected, it would be interesting to 
find out how long such individuals had been taking pain medications prior to 
surgery in order to address: (1 ) Is there a greater incidence of postoperative 
myalgia in those who suffer from chronic pain as opposed to those with acute 
pain? And (2) how would th is affect postoperative pain management? 
Obviously, these are questions to explore for future study. 
Type of Surgery and Postoperative Myalgia 
The population for this pi lot study involved only laparoscopic surgeries in an 
effort to distinguish postoperative myalg ia from incisional pain.  Therefore, this 
study involved the fol lowing various types of laparoscopic procedures: 
Diagnostic laparoscopic procedures (62%), cholecystectomies ( 1 5%), tubal 
l igations (1 5%) and herniorrhaphanies (8%) . However, because of the l imited 
population, not al l surgical types were represented within each study group. As 
previously d iscussed in this chapter, statistical analysis of each surg ical 
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Table 1 1 .  
Premedication Prior to Surgical Intervention and Postoperative Myalgia 
Premed 
use 
No 
Premed 
use 
1 .2 
1 
0.8 
0.6 
0.2 
0 
Figure 1 1 .  
Day 1 Standard 
Mean Deviation 
1 . 1 4  1 .22 
0.83 0.98 
Day 1 Day 2 Day 3 
Day 2 Standard .Day 3 Standard 
Mean Deviation Mean Deviation 
1 .00 1 .00 0.71 0.76 
0.50 0.84 0 .33 0.82 
■ Premed use 
, � No Premed use 
Premedication Prior to Surgical Intervention and Postoperative Myalgia 
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procedure in groups containing adequate numbers of subjects could yield 
significant statistical results. Since this was a pilot study, determining statistical 
significance was not a goal. Therefore, this section will only provide descriptive 
data on those subjects that agreed to participate in the study. As the data Table 
12 and Figure 12 illustrates, there was no statistical significance found between 
surgical type and postoperative myalgia. 
Diagnostic Laparoscopic Procedures 
Subjects undergoing diagnostic laparoscopic procedures were enrolled in the 
atracurium group (37.5%), lidocaine group (25%), and a combination 
atracurium/lidocaine group (37.5%). On postoperative day one six subjects 
(75%) having diagnostic procedures complained of pain, With pain scores ranging 
from mild to severe. All three subjects (100%) within the atracurium group had 
pain, reporting it as mild, moderate, or severe. On this same day, 50% (1 
subject) of the lidocaine group had moderate pain, and 66% (2 subjects) of the 
combination group had both mild and moderate pain. 
For postoperative day two, only five (63%) subjects complained of pain after a 
laparoscopic, diagnostic procedure. The lidocaine and combination groups did 
not differ in amount or rating of pain from day one. The only change came in the 
atracurium group. Here, only 2 subjects (66%) complained of pain, both 
reporting their pain as moderate. Therefore, it can be said that in this group, one 
patient felt better, and another felt worse on postoperative day two. 
On the third postoperative day, only four (50%) subjects continued to 
complain of myalgia after their diagnostic laparoscopic procedure. These 
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Table 1 2. 
Surgical Type and Postoperative Myalgia 
Day 1 
Pain 
Surgical 0.33 
Type 
Significance Day 2 
(Kruska-wa11is) Pain 
NS 0.21  
Significance Day 3 
(Kruskal-Wa11is) Pain 
NS 0.35 
• = Significant difference at the a = 0.05 level 
NS = Not Significant 
Day 1 Day 2 Day 3  
Figure 1 2. 
Surgical Type and Postoperative Myalgia 
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Significance 
(Krusta.Wallis) 
NS 
I £1 Surgical Type I 
comprised of 33% of the subjects in the atracurium group (1 subject), 50% of the 
subjects (1 subject) in the lidocaine group, and 66% of the subjects (2 subjects) 
in the combination group. As noted, in terms of percentages in the amount of 
pain, no change from day one was observed for the lidocaine group or the 
combination atracurium/lidocaine group except that pain was rated as mild in 
both groups. Although the greatest percentage of subjects complaining of pain 
(mild) were in the combination group, this observation could be deceiving, as the 
atracurium group had the worst description of pain (moderate) at the third 
postoperative day. Therefore, from a clinical practitioner's perspective, it is 
difficult to conclude which pretreatment group demonstrated a superior ability for 
preventing SCh-induced postoperative myalgia. 
Laparoscopic Cholecystectomies 
Laparoscopic Cholecystectomies comprised 15% of the surgical procedures 
performed on subjects enrolled in this study. This group was composed of only 
two subjects, with one subject representing the atracurium pretreatment group, 
and the other subject from the lidocaine pretreatment group. It is interesting to 
note that neither subject complained of pain on any of the three monitored 
postoperative days. Further analysis revealed that both subjects were female 
aged 40 and 41 , nonsmokers, in supine position during anesthesia, and taking 
pain medications prior to surgical intervention. Additionally, they were from two 
different ASA PSC groups (I and 1 1 , respectively). It was ironic that these two 
subjects had increased risk factors for postoperative myalgia, such as (1) being 
female, (2) being middle-aged, and (3) taking pain medications prior to surgery, 
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yet neither exhibited any reported postoperative pain. These results suggest that 
other factors, besides the administration of SCh may play a role in the 
development of postoperative myalgia. 
Laparoscopic Tubal Ligations 
Laparoscopic Tubal Ligations comprised 15% of the surgical procedures 
performed on subjects who agreed to participate in this study. However, only the 
combination atracurium/lidocaine pretreatment group underwent this type of 
surgical intervention. Therefore, descriptive analysis of this surgical group 
presents inconsistent results at best. For example, on postoperative day one, 
one subject reported no pain and the other reported moderate pain. On 
postoperative day number two, one subject continued to report no pain, while the 
other reported an improvement from moderate to only mild pain. However, on 
the last postoperative day, the individual who reported mild pain on day two 
digressed to moderate pain. The other subject continued to remain pain free for 
all three days. 
Further analysis revealed that both subjects were ASA PSC I females, aged 
28 and 26 years, nonsmokers, positioned supine during anesthesia, and did not 
take any medications prior to surgical intervention. Since these two subjects 
were very similar, pretreated with the same pretreatment group, and had very 
differing responses to pain, this once again is suggestive that some other 
mechanism may contribute to postoperative myalgia in subjects who receive 
SCh. 
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Laparoscopic Hemiorrhaphanies 
Laparoscopic hernia repairs consisted of only 8% (1  subject) of the surgical 
cases in this study. This subject was a 46 year-old male. He received 
atracurium as a pretreatment medication prior to the administration of SCh. 
Interestingly enough, he reported no pain for all three postoperative days. 
Further analysis revealed he was an ASA PSC I ,  nonsmoker, in supine position 
during anesthesia, and did not take any pain medications prior to surgical 
intervention. Thus, other than age, had very few risk factors associated with the 
development of postoperative myalgia. 
As one can see from these results, many factors can play a role in the 
development of postoperative myalgia. This study confirmed several trends, 
which have been previously reported within the literature in regards to 
postoperative pain and myalgia. These include that the incidence of 
postoperative myalgia following SCh administration is: ( 1) Greatest in females, 
(2) increased in incidence in those patients closer to age 50, and (3) greater in 
subjects who are forced (by necessity of the nature of surgery) to assume 
varying positions (other than supine) during the anesthetized period. The results 
of this author's study has raised many new potential questions focusing on 
issues of: (1) Cigarette smoking, (2) preoperative pain medication utilization prior 
to surgical intervention, (3) ASA PSC on postoperative myalgia/pain, and (4) the 
effect of the type of surgical intervention in relation to postoperative myalgia. 
Obviously, the relationship of SCh with postoperative myalgia warrants further 
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study. Most likely many factors including those mentioned above, as well as 
others, may be contributing to this complex and poorly understood phenomenon. 
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Chapter V 
Discussion 
Current literature suggests that the average incidence of postoperative 
myalgia is approximately 50% for patients that receive SCh without any 
pretreatment regimen (Wong & Chung, 2000). Although the relationship between 
SCh and myalgia is not well established, this author believes the literature that 
supports the theory that pretreatment will provide a protective effect against the 
occurrence of postoperative myalgia when SCh is utilized (Pace, 1990; Raman & 
San, 1997). However, as mentioned earlier, determining an efficacious 
pretreatment regime was not the goal of this study. Rather, determining 
feasibility of conducting a larger study, and documenting trends within a small, 
experimental population that might signify clinical significance, warrant the need 
for research in this area. Indeed, as the rest of this chapter will describe, this 
study provided the basis for the formation of numerous new research questions, 
as well as debate the findings of old research questions, regarding the 
phenomena of postoperative myalgia attenuation following the use of SCh as a 
component of a general anesthetic. 
Pretreatment Group Efficacy 
Although the exact cause of SCh-induced postoperative myalgia is unknown, 
the current standard pretreatment utilizes the administration of a nondepolarizing 
agent three minutes prior to SCh administration (Wong & Chung, 2000). 
However, many have argued that the use of lidocaine is as effective as 
nondepolarizing agents. Additionally, lidocaine does not cause unwanted side 
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effects such as undesirable intubating conditions, the need to use higher 
amounts of SCh and delayed return of spontaneous respiration (Haldia, Chatterji, 
& Kackar, 197 4 ). Furthermore, combination therapy utilizing lidocaine and a 
nondepolarizer have been shown to improve results in diminishing SCh-induced 
postoperative myalgia (Melnick, Chalasani, Uy, Phitayakorn, Mallett, & Rudy, 
1987). These potential benefits formed the basis of support for this author's 
choices of study pretreatment medications. 
As expected, due to the small sample size, analysis of data between 
postoperative myalgia and the efficacy of each pretreatment group did not reveal 
any of the pretreatments as superior for preventing postoperative myalgia. 
Recalling the study design, the three pretreatment groups were as follows: 
atracurium 0.05 mg/kg, lidocaine 1 .5  mg/kg, or the combination group of both 
atracurium 0.05 mg/kg and lidocaine 1 .5 mg/kg. Principal findings included the 
atracurium group having the most pain on postoperative day one, as 60% of the 
subjects within this group reported postoperative myalgia. Additionally, this 
group reported the most intense pain. The l idocaine and combination groups 
were comparable, as each reported a 50% incidence of postoperative myalgia on 
day one. Also, the combination group had the least intense pain. These findings 
are congruent with the literature (Raman & San, 1997) . However, on day two, 
although the atracurium group exhibited the most intense pain, it was found to 
have a decreased amount of pain, as only 40% of subjects reported 
postoperative myalgia. Both the lidocaine and combination group exhibited the 
same amount of reported pain (50%) , with the lidocaine group decreasing in 
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intensity and the discomfort of subjects in the combination group remaining the 
same as postoperative day one. By day three, this study found only 20% of 
subjects within the atracurium group to report myalgia. Additionally, this group 
reported the least intense pain of all three groups, followed by the combination 
group and then the lidocaine group. These findings are surprising, as it is 
inconsistent with the literature. Wong and Chung (2000), as well as Melnick, 
Chalasani, Uy, Phitayakorn, Mallett, and Rudy (1987), found that combination 
therapy was the best pretreatment therapy for postoperative myalgia. 
One possible reason for such differing findings in this pilot study may have 
been related to the timing of lidocaine administration. One study by Laurence 
(1987), found that lidocaine 1.5 mg/kg was ineffective in reducing postoperative 
myalgia when it was given two to three minutes prior to SCh. This was the 
administration routine in this author's study. Melnick (1987), however, found that 
lidocaine 1.5 mg/kg was effective at preventing postoperative myalgia, as long as 
it was given 15 to 30 seconds prior to SCh. Therefore, in a larger study, this may 
be a factor in producing similar findings within the literature. More importantly, 
this variable could be a plausible explanation for decreased postoperative 
myalgia. 
ASA Physical Status Classification and Cigarette Smoking 
To date, there are not any studies indicating that either ASA PSC or cigarette 
smoking would have an effect on postoperative myalgia. However, despite 
pretreatment, this data analysis indicated that some clinical significance might 
exist between ASA PCS, cigarette smoking, and postoperative myalgia. In this 
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authofs study, 80% of ASA PCS I I  subjects complained of pain, while only 
37.5% of ASA PCS I subjects had discomfort. Interestingly enough, 50% of the 
ASA PCS I I  subjects (two subjects) were also smokers. Although the small 
number of subjects prevents any generalizations to other populations (N=2), an 
interesting correlation was identified, which might prove to be a focus for future 
investigation. Such information could lead one to believe that perhaps ASA 
PCS and/or cigarette smoking may contribute to the development of 
postoperative myalgia. Thus, further study is needed in this area. 
Confounding Variables 
After putting this research study into action, several surprising confounding 
variables were identified. These factors made data collection more difficult and 
time consuming than anticipated. The most significant variable was with issues 
within the pharmacy. Because only one pharmacist works within this institution's 
surgical suite, and each subjects' dose of medication was customized by their 
weight, an average of forty-five minutes advanced notice was required to 
compound the needed regimen. Therefore, often times, enrolled subjects were 
excluded because of insufficient time to allow the pharmacist to compound the 
pretreatment medications. Access to a research pharmacist would have 
significantly decreased this time period, and allowed for inclusion of many more 
subjects. 
Additionally, because this author was responsible for the identifying plausible 
subjects, obtaining informed consent , notifying pharmacy, and providing the 
anesthetic care for the subject, there was limited ability to access eligible 
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subjects early enough for enrollment. In future studies, such variables could 
easily be avoided if one researcher were assigned to research duties, while 
another performed the anesthetic care. 
Limitations 
This pi lot study attempted to control for outside variables that were identified 
in the literature as causative factors for postoperative myalgia. Such factors 
included age, dose of SCh, type of operation, positioning of the patient, and 
ambulation after surgery (Wong & Chung, 2000). Despite such attention to 
detail, this author has noted several additional l imitations for this pi lot study. The 
following will summarize such instances, and recommend that a larger study 
incorporate controls in these areas in an effort to strengthen future research. 
As accepted by the nature of the project, one limitation of a pilot study is the 
sample size. This study's population consisted of a small convenience sample of 
15 subjects. Therefore, generalizations could not be made to any other 
populations. Additionally, gender specific information would be difficult to attain 
since this group was comprised of only two male subjects and 13 female 
subjects. However, this study was successfully implemented and it did 
determine feasibil ity to gather the needed information in order to complete a 
larger study. Since this goal was the overall purpose, the pilot study should be 
viewed as wholly successful and beneficial. 
Another l imitation of th is study is that it did not include a control group. 
Because past research has identified that postoperative myalgia occurs in 50% 
of the population receiving SCh without pretreatment, th is author felt it unethical 
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to include such a group in the study design (Wong & Chung, 2000). However, 
past studies have also identified a 20.8% incidence of postoperative myalgia for 
subjects who did not receive any pretreatment muscle relaxant before the 
administration of SCh (Trepanier, Brousseau, & Lacerte, 1988). Therefore, a 
control group could have been useful in identifying whether pretreatment 
medications made a difference in postoperative pain; Or " if the observed results 
were a phenomena due to some other factor. 
Some studies have implicated intubation as a causative factor of 
postoperative neck myalgia (Trepanier, Brousseau, & Lacerte, 1988). 
Incorporating a_n assessment tool to evaluate the ease or difficulty of intubation, 
and then comparing this score to those subjects who complained of 
postoperative neck myalgia, could strengthen the overall outcome of a larger 
study. This analysis would allow for differentiation between SCh-induced 
postoperative myalgia and positioning-induced postoperative neck myalgia. 
Strengths 
It is ironic that one of the greatest observed strengths of this author's study 
was thought to be a weakness at the beginning of the investigation. The 
assessment of postoperative myalgia for three days was thought to have many 
factors that would inhibit data collection. However; this author observed that all 
of the participants actually enjoyed being called by the researcher, and were 
more than happy to provide any information that was requested. As a result, this 
aspect of the study proved to .be an excellent public relations venture for this 
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surgical center. While completely unexpected, it demonstrates a value-added 
aspect to clinical research focusing on human subjects. 
Additional strengths included assessment of not only the amount of pain 
(PMS), but also differentiating postoperative myalgia from surgical pain, as well 
as describing the intensity of postoperative muscle soreness (PMES). Past 
studies have focused on either PMS or PMES, but not both. Consequently, 
former studies have had difficulty in distinguishing myalgia from surgical pain. 
This author very quickly realized the importance of using both tools in this 
investigation. For example, the PMS was sensitive enough to help the 
investigator assure the subject was experiencing true myalgia, and not shoulder 
discomfort from surgical gas. Using two valid assessment tools strengthens the 
findings, and provides a more complete picture of postoperative myalgia in this 
pilot study. Therefore, suggesting that a larger project utilizing the same type of 
assessment tools and framework should be able to provide more complete 
answers to the mystery of postoperative myalgia. 
· Conclusion 
Overall, this pilot study accomplished its purpose, thereby determining 
feasibility for a larger study. Although not statistically significant, the data 
obtained through the implementation of this pilot study identified areas that are 
clinically significant. Study results also identified other potential causative factors 
for postoperative myalgia, such as ASA PCS, cigarette smoking, surgical 
position, prior use of pain medications, and surgical type. Because so much 
remains controversial about the phenomena of postoperative myalgia, this 
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remains an area where intense research needs to be applied, so as to determine 
which interventions constitute the best practices to provide better care in the 
future. 
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Appendix A 
ASA Physical Status Classification 
http://www.asahq.org/clinical/physicalstatus.htm 
ASA Physical Status Classification 
Class 1 A normal healthy patient. 
Class 2 A patient with mild systemic disease and no functional limitations. 
Class 3 A patient with moderate to severe systemic disease that results in 
some functional limitations. 
Class 4 A patient with severe systemic disease that is a constant threat to life 
and functionally incapacitating. 
Class 5 A moribund patient who is not expected to survive 24 hours with or 
without surgery. 
Class 6 A brain-dead patient whose organs are being harvested. 
Class E If the procedure is an emergency, an "E" follows the physical status 
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Appendix B 
Study Formulary 
Study Formulary: Indications, contraindications, and adverse effects are from 
Micro Medex®. All dosages are commonly administered and accepted ranges for 
use in anesthesia. It is important to note that responses to adverse effects are 
not drug specific, and anesthesia providers will respond in a uniform way. 
❖ Albuterol (Proventi l) 1 -2 puffs prn 
► Indications 
• bronchospasm 
• exercised induced asthma 
► Contraindications 
• hypersensitivity to albuterol 
► Adverse effects 
• bronchospasms 
• arrhythmias 
• tremors/nervousness 
• palpitations 
• tachycardia 
• hypertension 
• hypokalemia 
• hyperglycemia 
❖ Atracurium (Tracrium) 0.05 mg/kg (defasciculating dose) 
► Indications 
• muscle relaxation 
• adjunct to anesthesia 
► Contraindications 
• hypersensitivity to atracurium 
► Adverse effects 
• flushing 
• hypotension 
• bradycardia 
• bronchospasm 
• tachycardia 
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❖ Atropine Sulfate 0.4 - 1 .0 mg 
► Indications 
• symptomatic bradycardia 
• bradyarrhythmias 
► Contraind ications 
• narrow angle glaucoma 
• myasthenia gravis 
• paralytic i leus 
► Adverse effects 
• tachycardia 
• slight mydriasis 
• hot, flushed skin 
❖ Dobutamine hydrochloride (Dobutrex) 2.5 - 1 0  mcg/kg/min 
► Ind ications 
• increase cardiac contraction 
► Contraindications 
• hypersensitivity to Dobutamine hydrochloride 
• hypersensitivity to sulfonamides . 
• IHSS (idiohypertrophic subaortic stenosis 
► Adverse effects 
• increased heart rate 
• hypertension 
• premature ventricular contractions 
❖ Decadron (Dexamethasone) 4-Smg 
► Ind ications 
• ad renal insufficiency 
• inflammatory disorders 
• nausea/vomiting 
• shock 
► Contraindications 
• hypersensitivity to class 
• systemic fungal infection 
► Adverse effects 
• adrenal insufficiency 
• steroid insufficiency 
• immunosuppression 
1 09 
❖ Dolasetron (Anzemet) 1 2.5 mg 
► Indications 
• antiemetic 
► Contraindications 
• hypersensitivity to dolasetron products 
► Adverse effects 
• headache 
• dizziness 
• drowsiness 
• pain 
❖ Dopamine hydrochloride (lntropin) 2- 20 mcg/kg/min 
► Indications 
• correct hypotension 
• increase cardiac output 
• improve perfusion 
► Contraindications 
• uncorrected tachyarrythmias 
• pheochromocytoma 
• ventricular fibrillation 
► Adverse effects 
• arrhythmias 
• hypotension 
❖ Ephedrine 5-10 mg pm 
► Indications 
• asthma 
• hypotension 
► Contraindications 
• hypersensitivity to ephedrine/sympathomimetic amines 
• thyrotoxicosis 
► Adverse effects 
• central nervous system stimulation 
• hypertension 
• palpitations 
• tremor 
1 1 0 
❖ Epinephrine hydrochloride (Adrenalin Chloride} 0.01 - 0.03 mcg/kg/min 
► Indications 
• anaphylaxis 
• bronchospasm 
• restore cardiac rhythm 
► Contraindications 
• narrow angle glaucoma 
• coronary insufficiency 
• organic brain damage 
► Adverse effects 
• hypertension 
• tachycardia 
• ventricular fibrillation 
❖ Esmolol (Brevibloc} 0.25 mg/kg � 1 .0 mg/kg 
► Indications 
• supraventricular tachycardia 
• hypertension 
► Contraindications 
• hypersensitivity to esmolol/ beta-blockers 
• sinus bradycardia 
• 2nd, 3rd, degree AV block 
• cardiogenic shock 
► Adverse effects 
• bronchospasm 
• severe hypotension 
• cardiac failure 
• nausea and vomiting 
• phlebitis 
❖ Fentanyl (Sublimaze} 0.7- 2 mcg/kg 
► Indications 
• pain 
• analgesic adjunct to anesthesia 
• anesthesia 
• acute or postoperative pain 
► Contraindications 
• hypersensitivity to Fentanyl 
► Adverse effects 
• respiratory depression 
• muscle rigidity 
• nausea and vomiting 
• sedation 
1 1 1  
❖ Glycopyrrolate (Robinal) 0.007mg/kg 
► Indications 
• gastric and salivary secretion reduction 
• vagal-mediated bradycardia 
• peptic ulcer 
• neuromuscular blockade reversal 
► Contraindications 
• glaucoma 
• obstructive uropathy 
• myasthenia gravis 
• severe ulcerative colitis 
• unstable cardiovascular status 
► Adverse effects 
• dry mouth 
• blurred vision 
• tachycardia 
• urinary retention 
❖ Granisetron Hydrochloride (Kytril) 1 0-20mcg/kg 
► Indications 
• postoperative nausea and vomiting 
► Contraindications 
• hypersensitivity to grainisetron products 
► Adverse effects 
• headache 
• constipation 
• asthenia 
• diarrhea 
• abdominal discomfort 
❖ Hydroxyl ethyl starch (Hextend) 6% 20 mUkg 
► Indications 
• volume expander 
• hypotension 
• blood loss 
► Contraindications 
• hypersensitivity 
► Adverse reactions 
• hypertension 
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❖ Ketrolac (Toradol) 30mg 
► Indications 
• short-term management of . pain 
► Contraindications 
• hypersensitivity to nonsteroidal anti-inflammatory drugs 
• gastrointestinal ulcers 
► Adverse effects 
• edema 
• hypertension 
• puritus 
• nausea 
• vomiting 
• G. I. bleeding 
• flushing 
❖ Labatolol (Trandate) 0.1 - 0.25 mg/kg 
► Indications 
• hypertension 
• hypertension emergency 
► Contraindications 
• hypersensitivity to labatolol/ beta-blockers 
• congestive heart failure 
• hepatic failure 
• pheochromocytoma 
■ 2nd, 3rd, degree AV block 
• severe bradycardia 
► Adverse effects 
• ventricular arrhythmias 
• bronchospasm 
• SLE 
• hypotension 
• nausea and vomiting 
• urinary retention 
• rash 
• muscle spasms 
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❖ Lidocaine (Xylocaine) 1 .5. mg/kg 
► Indications 
• ventricular arrhythmias 
• anesthesia 
► Contraindications 
• hypersensitivity to lidocaine/amide-type anesthetics 
► Adverse effects 
• seizures 
• drowsiness 
• tremors 
• hypotension 
❖ Midazolam (Versed) 0.02-0.1 mg/kg 
► Indications 
• anesthesia induction 
• conscious sedation 
► Contraindications 
• acute narrow angle glaucoma 
• hypersensitivity to benzodiazepines 
► Adverse effects 
• amnesia 
• nausea and vomiting 
• respiratory depression 
❖ Morphine 0.05 - 0 .2 mg/kg 
► Indications 
• for management of moderate to severe pain 
• preoperative sedation 
• anesthesia supplement 
► Contraindications 
• hypersensitivity to opiates 
• paralytic ileus 
• acute/severe asthma 
• upper airway obstruction 
► Adverse effects 
• hypotension 
• respiratory depression 
• nausea 
• sedation 
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❖ Neostigmine (Prostigmine) 0.04 - 0.07mg/kg 
► Indications 
• myasthenia gravis 
• neuromuscular blockade reversal 
• post-op paralytic ileus 
• urinary retention 
► Contraindications 
• hypersensitivity to neostigmine 
• intestinal or urinary obstruction 
• peritonitis 
► Adverse effects 
• bradycard ia 
• psychosis 
• agitation 
• abdominal distention 
• constipation 
❖ Nitroglycerin (Deponit) 0.1 - 7 .0 mcg/kg/min 
► Indications 
• To control hypertension associated with surgery 
► Contraindications 
• hypersensitivity to nitrites 
• head trauma 
• severe anemia 
► Adverse effects 
• hypotension 
• tachycardia 
• flushing 
❖ Nitrous Oxide 10 - 70°/4 
► Indications 
• anesthetic adjunct 
► Contraindications 
• pneumothorax 
• increased intracranial pressure 
• increased lntraocular pressure 
► Adverse effects 
• nausea/vomiting 
• abdominal distention 
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❖ Ondansetron Hydrochloride (Zofran) 4 mg 
► Indications 
• nausea and vomiting 
► Contraindications 
• hypersensitivity to ondansetron 
► Adverse effects 
• elevated liver function tests 
■ headache 
• diarrhea 
❖ Phenylephrine (Neo-synephrine) 50-100 mcg pm 
► Indications 
• decongestant 
• hypotension 
► Contraindications 
• hypersensitivity to phenylephrine 
• narrow angle glaucoma 
• hypertension 
• coronary artery disease 
► Adverse effects 
• tachycardia 
• hypertension 
• myocardial infarction 
• subarachnoid hemorrhage 
❖ Promethazine (Phenergan) 6.25 - 25mg 
► Indications 
• nausea and vomiting 
• sedation 
• allergic reactions 
► Contraind ications 
• narrow-angle glaucoma 
• peptic ulcer disease 
• prostatic hypertrophy 
• bladder obstruction 
• MAOI therapy 
• hypersensitivity to phenothiazines 
► Adverse effects 
• drowsiness 
• xerostomia 
• dizziness 
• extra pyramidal reactions 
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❖ Propofol (Diprivan) 2-2.5 mg/kg 
► Indications 
• anesthesia 
• sedation 
► Contraindications 
• hypersensitivity to eggs 
► Adverse effects 
• seizures 
• hypotension 
• apnea 
• injection site pain 
• cardiac arrest 
❖ Sevoflurane (Ultane) 0.5 - 6% 
► Indications 
• anesthesia 
► Contraindications 
• hypersensitivity to sevoflurane 
• patients with susceptibility to malignant hyperthermia 
► Adverse effects 
• nausea and vomiting 
• excitatory movements 
• respiratory depression 
• decreased heart rate 
❖ Succinylcholine (Anectine) 1 .5mg/kg 
► Indications 
• muscle relaxation 
• intubation 
► Contraindications 
• malignant hyperthermia 
• acute phase of major trauma/major burns 
• hypersensitivity to succinylcholine 
• skeletal muscle myopathies 
• upper motor neuron injury 
► Adverse effects 
• myoglobinemia 
• prolonged muscle relaxation 
• bradycardia 
• hyperkalemia 
• respiratory depression/apnea 
• hypersensitivity reactions 
• cardiac arrest 
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❖ Vecuronium (Norcuron) 0.05- 0.1 mg/kg 
► Indications 
• muscle relaxation 
► Contraindications 
• hypersensitivity to pancuronium or vecuronium products 
► Adverse effects 
• bronchospasm 
• bradycardia 
• hypotension/hypertension 
• tachycardia 
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Appendix C 
Informed Consent 
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and severity of Postoperative 
Myalgia 
Investigators 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell , BSN, 
SRNA 
Informed Consent 
The study in which you are asked to participate has the goal of reducing muscle 
twitching and muscular soreness after surgery, which can occur with 
succinylcholine administration. This is a topic that is frequently studied. Many 
scientists feel that the muscle soreness some people experience after surgery is 
related to the muscle twitching occurring with succinylcholine administration. You 
are being asked to participate because you are in a group of patients who 
frequently have muscle soreness after surgery, namely, patients receiving 
succinylcholine for general tracheal anesthesia. 
Succinylcholine is a muscle relaxant that allows your anesthesia provider to 
place a breathing tube in your windpipe to protect your airway after you are 
asleep. This tube allows you to breath the anesthetic gases that will keep you 
asleep. This is done routinely for general anesthesia and will be required 
regardless of your participation in this study. You should be unaware of this tube 
placement and should not remember it. All subjects will be selected from the 
daily surgical schedule at the University of Tennessee Medical Center. 
This study will examine two anesthetic medications that are routinely used to 
prevent muscular twitching and soreness. Neither drug has been proven superior 
in preventing muscle twitching or muscular soreness. We are asking permission 
to do two things during this study. First, to record any muscular twitching we may 
observe, and second, to ask you some simple questions after surgery about 
whether you are experiencing any muscular soreness. You will be contacted by 
phone 24, 48, and 72 hours after your surgery by one of the investigators. ·1f your 
surgeon admits you to the hospital, you will be visited in your room by one of the 
investigators. 
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· A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-ind�ced Fasciculation and severity of Postoperative 
Myalgia 
Investigators 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, 
SRNA 
· The medications used will consist of a muscle relaxant (atracurium), or local 
anesthetic/numbing (lidocaine) medication. Some patients may receive both 
medications. These medications will be administered in a double blind method. 
This means that neither you nor the anesthesia provider will know which drug 
was given until the conclusion of the study. The doses of the medicines, 
however, will be carefully and safely prepared for you under the supervision of a 
licensed pharmacist. You will receive standard and acceptable doses of all 
medications, just as you would if you chose not participate in this study. They will 
look the same, and no one except the pharmacist will know what you received 
until all the patients have been studied. 
You will be assigned a unique number that will be used to identify you and the 
information we gather. If something were to happen that required the knowledge 
of what drug you received we would use that number to obtain the necessary 
information. There may be around 100 patients involved in this study, and it will 
probably take several months to gather all the information we need. 
Risks Associated with Participation 
Since the medications you will receive today are routinely used for anesthetics, 
there is essentially no increased risk to you associated with your participation in 
this study. However all medications have side effects and could cause adverse 
reactions. Although rare, some possible side effects that could occur include 
nausea, vomiting, sedation, prolonged muscle weakness, high potassium, 
increased body temperature, and seizures. 
If you experience the common side effects of pain, nausea, or vomiting after your 
surgery, standard medications for these conditions will be administered, just as 
they would be for anyone else. You are not expected to experience any 
increased discomfort as a result of your participation in this study. 
All records are kept confidential. As stated earlier you will be assigned a number 
which will be used as your identifier, rather than using your name. These records 
will be kept in the Anesthesia Office under lock and key for a period of five years 
from the conclusion of the study. After five years, they will be destroyed. 
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Succinylcholine-induced Fasciculation and severity of Postoperative 
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Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, 
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The hope is to gain information from this study that may help patients in the 
future with their post-surgery recovery. The potential benefits to the subjects may 
include a more comfortable recovery time and possibly an earlier return to their 
pre-surgery level of function. All future patients who undergo surgery and receive 
succinylcholine could potentially benefit from this study. If this study 
demonstrates that one or the combination of pretreatment medications has 
superior ability to diminish or prevent muscle twitching and muscular soreness, 
then future patients may experience less discomfort after surgery. 
Alternatives to participation 
There is no superior drug or treatment to prevent succinylcholine induced muscle 
twitches or muscular soreness. 
Confidentiality 
Although study results may be published, your confidentiality will be maintained. 
Your name or information identifying you will not be released without written 
permission unless required by law. Under federal privacy regulations, you have 
the right to determine who has access to your personal health information ( called 
"protected health information" or PHI). PHI collected in this study may include 
your medical history, the results of physical exams, lab tests, x-ray exams, and 
other diagnostic / treatment procedures, as well as basic demographic 
information. By signing this consent form, you are authorizing the researchers at 
the University of Tennessee Medical Center to have access to your PHI collected 
in this study and to receive your PHI from (Jack Chavez M.D.) ,  and may the 
University of Tennessee Medical Center where you have received health care. In 
addition, your PHI may be shared with other persons involved in the conduct or 
oversight of this research, including the (FDA) Food and Drug Administration, the 
University of Tennessee Medical Center, and the University of Tennessee 
Graduate School of Medicine Institutional Review Board. Your PHI will not be 
used or disclosed to any other person or entity, except as required by law, or for 
authorized oversight of this research study by other regulatory agencies, or for 
other research for which the use and disclosure of your PHI has been approved 
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by the IRB. Your PHI will be used indefinitely. You may cancel this authorization 
in writing at any time by contacting the Principal Investigator listed on the first 
page of the consent form. If you cancel the authorization, continued use of your 
PHI is permitted if it was obtained before the cancellation and its use is 
necessary in completing the research. However, PHI collected after your 
cancellation may not be used in the study. If you refuse to provide this 
authorization, you will not be able to participate in the research study. 
If you cancel the authorization, then you will be withdrawn from the study. 
Finally, the federal regulations allow you to obtain access to your PHI collected or 
used in this study. However, in order to complete the research, your access to 
this PHI may be temporarily suspended while the research is in progress. When 
the study is completed, your right of access to this information will be reinstated. 
You understand that you are not waiving any legal rights or releasing the hospital 
or its agents from liability for negligence. You understand that in the event of 
physical injury resulting from research procedures, the University of Tennessee 
does not have funds budgeted for compensation either from lost wages or for 
medical treatment. Therefore, the University does not provide reimbursements 
for such injuries. 
By signing this form, you indicate that: You have read the description of the 
above study and have freely volunteered to participate in it. You have had 
possible side effects and adverse reactions explained to you and have had 
alternative therapies explained. You have had an opportunity to ask questions of 
the investigator and have received acceptable answers. You understand you 
may withdraw from this study at any time and will still receive standard treatment 
for your condition. 
Payment for Participation 
There is no payment in any form to study participants. 
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Costs of Participation 
There are no additional costs to you for participating in this study. 
Contact/Questions 
If you have any questions about the nature of this study, or feel that you have 
had an adverse reaction, please feel free to contact Jack Chavez, MD at (865-
544-9220), Tonya Campbell (865-544-9220), or Fred Schrimpe (865-544-9220). 
If you have any questions about your rights as a research subject, please call the 
Institutional Review Board at (865-544-9781 ). Thank you for your consideration. 
Consent of Subject 
I have read or have had read to me the description of the research study as 
outlined above. The investigator or his/her representative has explained the 
study to me and has answered all of the questions I have at this time. I have 
been told of the potential risks, discomforts, side effects and adverse reactions 
as well as the possible benefits (if any) of the study. 
I freely volunteer to participate in this study. I understand that I do not have to 
take part in this study and that my refusal to participate will involve no penalty or 
loss of rights too which I am entitled. I further understand that I am free to later 
withdraw my consent and discontinue participation in this study at any time. I 
understand that refusing to participate or later withdrawing from the study wi'II not 
adversely affect my subsequent medical care. 
Signature Date -------------- ----
Investigator Signature Date __ _ 
Witness Date __ _ 
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Appendix D 
lnvestigational Review Board Approval Letters 
THE UNIVERSITY OF TENNESSEE 
GRADUATE SCHOOL OF MEDICINE 
March 20, 2003 
Jack Chavez, MD 
Department of Anesthesiology 
· The University of Tennessee Medical Center 
1 924 Alcoa Highway 
Knoxville, TN 37920 
Office of lmtitutioaal Review Board 
FWA 2301 
1924 Alcoa Highway· 
Knoxville, TN 3 7920-6999 
(865) 544-9781 
FAX (865) 544-9275 
RE: IRB #2233 •A Comparison of the Differential Effects of Atracurium and/or 
Lidocaine on Succinylcholine-induced Fasciculation and the Severity of 
Postoperative Myalgia· 
Dear Dr. Chavez, 
On March 18, 2003, the University of Tennessee Graduate School of Medicine in 
Knoxville Institutional Review Board reviewed your above referenced application. The 
Board voted full approval with no abstentions on this prot�I including i�formed 
consent form. Your research application will be reviewed in one year. 
The Institutional Review Board ·is in compliance with the requirements in Part 50, 
56, Subch�pter D. Part 31 2 of the 21 Code of Federal ·Regulations published January 27, 
1981 . 
Any alterations in ·the protocol must be promptly reported to the Institutional 
Review Board. In addition, annual reapproval (February 2004} is required by the IRB, 
and it is your responsibility as the Principal Investigator to initiate the request'for approval 
regardless of the time the study has been approved by the sponsoring agency. 
You have individual responsibility for reporting to the Board in the event of adverse 
:: : 
��� <r-,U.i.. 
Joseph E. Fuhr, PhD 
Chairman 
Institutional Review Board 
JEF: rt 
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THE UNIVERSITY OF TENNESSEE 
May 16, 2003 
IR.B #: 6413 B 
Institutional Review Boan: 
Office of Rescan± 
404 Andy Holt T owei 
Knoxville, Tennessee 3 7996.014( 
865-974-346t 
Fax: 865-974-280� 
Title: A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and Severity of Postoperative Myalgia 
Tonya Campbell 
Anesthesia 
UTMCK. 
1924 Alcoa Hwy. 
John Preston, Advisor 
Nursing 
1200 Volunteer Blvd. 
Campus 
Jack �vez, Co-PI 
Anesthesia 
UTMCK 
1924 _Alcoa Hwy. 
Fredrick Schrimpe, Co-PI 
Anesthesia 
UTMCK 
1974 Alcoa Hwy. 
. . 
At the meeting of the Institutional Review Board (IRB) held May 15, 2003� the above protocol 
was reviewed and approved. 
This �val for a period ending one year from the �-of this letter. Please make timely 
sub�on of renewal or prompt notificati� of project termination (see item #3 below). 
Responsibilities of the investigator during the conduct of this project include the following: 
1. Prior approval from the :Commi� before insti� any changes in the project 
2. To retain signed consent fonns from subjects for at least three years following 
completion of the project 
3. To submit a Form D to report changes in the project or to report termination at 12-
month or less intervals. 
The Committee wishes you every success in your research endeavor. · This office will send you a 
renewal notice (Form R) on the anniversary of your approval date. 
Sincerely, 
�A .· -M � � -�� 
� n 
Compliances 
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Appendix E 
Standard ASA Monitors 
ANESTHESIA STANDARDS FOR BASIC INTRAOPERATIVE MONITORING 
Note: Within these standards, "Anesthesia" is defined as all types of anesthesia 
care unless otherwise specified by the text. 
STANDARDS FOR BASIC ANESTHETIC MONITORING 
(Approved by House of Delegates on October 21 , 1 986 and last amended on 
October 21 , 1 9981) 
http://www.asahq.org/publicationsAndServices/standards/02. html 
These standards apply to all anesthesia care although, in emergency 
circumstances, appropriate life support measures take precedence. These 
standards may be exceeded at any time based on the judgment of the 
responsible anesthesiologist. They are intended to encourage quality patient 
care, but observing them cannot guarantee any specific patient outcome. They 
are subject to revision from time to time, as warranted by the evolution of 
technology and practice. They apply to all general anesthetics, regional 
anesthetics and monitored anesthesia care. This set of standards addresses only 
the issue of basic anesthetic monitoring, which is one component of anesthesia 
care. In certain rare or unusual circumstances, 1 )  some of these methods of 
monitoring may be clinically impractical, and 2) appropriate use of the described 
monitoring methods may fail to detect untoward clinical developments. Brief 
interruptions of continualtl monitoring may be unavoidable. Under extenuating 
circumstances, the responsible anesthesiologist may waive the requirements 
marked with an asterisk (*); it is recommended that when this is done, it should 
be so stated (including the reasons) in a note in the patient's medical record. 
These standards are not intended for application to the care of the obstetrical 
patient in labor or in the conduct of pain management. 
STANDARD I 
Qualified anesthesia personnel shall be present in the room throughout the 
conduct of all general anesthetics, regional anesthetics and monitored 
anesthesia care. 
OBJECTIVE 
Because of the rapid changes in patient status during anesthesia , qualified 
anesthesia personnel shall be continuously present to monitor the patient and 
provide anesthesia care. In the event there is a direct known hazard, e.g. , 
radiation, to the anesthesia personnel, which might require intermittent remote 
observation of the patient, some provision for monitoring the patient must be 
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made. In the event that an emergency requires the temporary absence of the 
person primarily responsible for the anesthetic, the best judgment of the 
anesthesiologist will be exercised in comparing the emergency with the 
anesthetized patient's condition and in the selection of the person left responsible 
for the anesthetic during the temporary absence. 
STANDARD II 
During all anesthetics, the patient's oxygenation, ventilation, circulation and 
temperature shall be continually evaluated. 
OXYGENATION 
OBJECTIVE 
To ensure adequate oxygen concentration in the inspired gas and the blood 
during all anesthetics. 
METHODS 
Inspired gas: During every administration of general anesthesia using an 
anesthesia machine, the concentration of oxygen in the patient breathing system 
shall be measured by an oxygen analyzer with a low oxygen concentration limit 
alarm in use. * 
Blood oxygenation: During all anesthetics, a quantitative method of assessing 
oxygenation such as pulse oximetry shall be employed. * Adequate illumination 
and exposure of the patient are necessary to assess color. * 
VENTILATION 
OBJECTIVE 
To ensure adequate ventilation of the patient during all anesthetics. 
METHODS 
Every patient receiving general anesthesia shall have the adequacy of ventilation 
continually evaluated. Qualitative clinical signs such as chest excursion, 
observation of the reservoir breathing bag and auscultation of breath sounds are 
useful. Continual monitoring for the presence of expired carbon dioxide shall be 
performed unless invalidated by the nature of the patient, procedure or 
equipment. Quantitative monitoring of the volume of expired gas is strongly 
encouraged. *  
When an endotracheal tube or laryngeal mask is inserted, its correct positioning 
must be verified by clinical assessment and by identification of carbon dioxide in 
the expired gas. Continual end-tidal carbon dioxide analysis, in use from the time 
of endotracheal tube/laryngeal mask placement, until extubation/removal or 
initiating transfer to a postoperative care location, shall be performed using a 
quantitative method such as capnography, capnometry or mass spectroscopy. * 
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When ventilation is control led by a mechanical venti lator, there shall be in 
continuous use a device that is capable of detecting disconnection of 
components of the breathing system. The device must g ive an audible signal 
when its alarm threshold is exceeded . 
During regional anesthesia and monitored anesthesia care, the adequacy of 
ventilation shall be evaluated, at least, by continual observation of qual itative 
clinical signs. 
CIRCULATION 
OBJECTIVE 
To ensure the adequacy of the patient's circulatory function during all 
anesthetics. 
METHODS 
Every patient receiving anesthesia shal l  have the ·electrocardiogram continuously 
d isplayed from the beginning of anesthesia until preparing to leave the 
anesthetizing location. * 
Every patient receiving anesthesia shall have arterial blood pressure and heart 
rate determined and evaluated at least every five minutes. * 
Every patient receiving general anesthesia shall have, in  addition to the above, 
circulatory function continually evaluated by at least one of the fol lowing: 
palpation of a pulse, auscultation of heart sounds, monitoring of a tracing of intra­
arterial pressure, ultrasound peripheral pulse monitoring, or pulse 
plethysmography or oximetry. 
BODY TEMPERATURE 
OBJECTIVE 
To aid in the maintenance of appropriate body temperature during all 
anesthetics . 
METHODS 
Every patient receiving anesthesia shall have temperature monitored when 
cl in ically significant changes in body temperature are intended, anticipated or 
suspected . 
#Note that "continual" is defined as "repeated regularly and frequently in steady 
rapid succession" whereas "continuous" means "prolonged without any 
interruption at any time." 
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Appendix F 
Acceptable Hemodynamic Monitoring Parameters 
+/- 20% of baseline: Heart rate 
+/- 20% of baseline: Blood Pressure 
95% or above: Oxygen Saturation 
35.6 C (96.0 F) - 37.8 C (1 00.0 F): Temperature 
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Appendix G 
Extubation Criteria 
Train of four is 4/4 without fade, and a positive sustained tetanus 
Spontaneous respirations of >8, with a tidal volume of >250 
Negative lnspiratory pressure (N IP) of -1 0 
Eye opening to voice, or purposeful movement 
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Appendix H 
Postoperative Myalgia Evaluation Scale (PM'ES) 
0 = Absence of pain other than characteristic surgical gas pain 
1 = Mild muscle stiffness or pains, when specifically asked about, in the nape of 
the neck, or in shoulders and lower chest on deep breathing 
2 = Moderate muscle stiffness and pains spontaneously complained of by the 
patient 
3 = Severe, incapacitating, generalized muscle stiffness or pain 
Subject # 0 1 ' 2 3 
1 
2 
3 
4 
5 
6 
7 
8 
9 
1 0  
1 1  
1 2  
1 3  
1 4  
1 5  
1 6  
1 7  
1 8  
1 9  
20 
21 
22 
23 
24 
Did the recovery room nurse report the patient shivering in the recovery room? 
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Appendix I 
Postoperative Myalgia Survey (PMS) 
Date of the telephone call ___ Postoperative Day: 1_· 2_ 3_ 
Subject's study number: Date of surgery: __ Type of surgery: __ 
1. Do you have any soreness or stiffness in your body besides headache or 
surgical gas pains? Yes_ No_ 
2. Have you been up and about (ambulatory)? Yes_ No_ 
3. Is there pain and stiffness in the muscles? Yes_ No _ 
4. In which sites do you have muscle pain/stiffness? 
Jaw_ Throat_ Neck_ Shoulder_ Arms_ Chest_ Abdomen 
Back_ Buttocks_ Thighs_ Calves_ General ized_ 
5. When did you first notice the pain? � 
6. Rate the muscle stiffness/pain on a score 0-10 (0 being no pain, and 10 the 
worst pain ever) only on the sites reported to be painful by the patient. 
Jaw_ Throat_ Neck_ Shoulders_ Arms_ Chest_ Abdomen_ 
Back_ Buttocks_ Thighs_Calves_ Generalized_ 
7. What makes the muscle stiffness/pain worse? Movement_ Rest_ 
8. Describe the muscle pain/stiffness in your own words. 
9. Do you think the muscle pain is restricting your normal activity? Yes_ No _ 
10. Is the muscle pain preventing you from getting out of bed? Yes_ No_ 
11. How would you rate this l imitation of activity on a scale of 0-1 0? (0 being no 
limitation in activity, 10 being muscle pain limiting the patient to bed all the 
time except for essential activity) 
12. Do you think the muscle pain is severe enough for you to take extra pain 
medication? Yes_ No 
13. Are you taking your prescribed pain medication to help your surgical pain or 
muscle pain? Yes_ No_ 
14. How many pain pills have you taken the last 24 hours?_ 
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1 
2 
3 
4 
5 
6 
7 
8 
9 
1 0  
1 1  
1 2  
1 3  
1 4  
15  
16  
1 7  
1 8  
19  
20 
21 
22 
23 
24 
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Name Phone 
# 
Appendix J 
Demographic Data Sheet and Master Subject List 
Subject ASA w.. Ht. in Gender Smoking Pre-op Pre-op Post- Post-op 
# in inches hx/# of NSAID NSAID op NSAID 
kg yrs NARC NARC NSAI D NARC 
NARC 
dose duration dose duration 
Vita 
Tonya Lynn DeWitt Campbell was born in Morgantown, West Virginia on June 
27, 1969. She was raised in Springboro, Ohio and went to grade school at 
Clearcreek Elementary. Immediately following grade -school, she moved and 
attended Bayonet Point junior high school in Bayonet Point, Florida. She 
graduated from Gulf High· School in 1987. From there, she went to Maryville 
College, located in Maryville, Tennessee and received a Bachelor of Arts in 
Health Sciences in 1994. In 1995, she graduated with an Associates of Nursing 
from Roane State Community College, in Knoxville, Tennessee. She continued 
her education and received a Bachelor of Science in Nursing from the University 
of Tennessee, Knoxville in 2001. 
After working as a critical care nurse for seven years, Tonya is currently 
pursuing her Master's in Nursing, with a concentration in Nurse Anesthesia, at 
the University of Tennessee in Knoxville, Tennessee. Future plans include a job 
in Corbin, Kentucky as a nurse anesthetist after graduation on December 14, 
2003. 
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